

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 20, 2005, 05:59:01 ; Search time 17 Seconds  
(without alignments)  
2190.346 Million cell updates/sec

Title: US-10-800-249-2  
Perfect score: 2081  
Sequence: 1 MNRHLLQDHFLEIDKKNCCV.....KGHCHOEPASLEKOLGCCIE 387

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR 79:\*  
1: pir1:\*  
2: pir2:\*  
3: pir3:\*  
4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1990	95.6	387	2	I69202
2	431	20.7	362	2	S33733
3	415	19.9	373	2	JC4182
4	407	19.6	373	2	JC4737
5	351.5	16.9	308	2	I50241
6	350.5	16.8	364	2	JQ1488
7	348.5	16.7	370	2	JC5549
8	348	16.7	328	2	I55450
9	341	16.4	399	2	I48705
10	339.5	16.3	344	2	T09508
11	337	16.2	373	2	A47556
12	337	16.2	397	2	S66518
13	333	16.0	342	2	A40191
14	330.5	15.9	384	2	A47249
15	326.5	15.7	366	1	QORT82
16	326	15.7	380	2	JC2338
17	325	15.6	380	2	A55259
18	324.5	15.6	380	2	S36143
19	323	15.5	328	2	JC4800
20	323	15.5	365	2	S68679
21	323	15.5	425	2	A37912
22	322.5	15.5	380	2	A48227
23	322	15.5	388	2	JN0605
24	321	15.4	420	2	I51667
25	320	15.4	366	2	I49519
26	317	15.2	369	2	JC5088
27	317	15.2	391	2	C41795
28	317	15.2	391	2	A39297
29	316	15.2	391	2	A41795

30	315.5	15.2	369	2	B41795
31	314.5	15.1	342	2	S13638
32	314.5	15.1	369	2	JC2083
33	314.5	15.1	380	2	JC2434
34	314.5	15.1	384	2	JC4629
35	313.5	15.1	369	2	A45291
36	313.5	15.1	432	2	A43448
37	310	14.9	341	2	S63666
38	310	14.9	341	2	S43252
39	309	14.8	398	2	A57510
40	308.5	14.8	398	2	I56517
41	307.5	14.8	364	2	JN0763
42	307	14.8	418	2	A46226
43	306	14.7	355	2	I49339
44	305.5	14.7	372	2	I38532
45	305	14.7	355	2	A45177

ALIGNMENTS

RESULT 1

I69202  
G protein-coupled receptor HM74 - human  
C:Species: Homo sapiens (man)  
C>Date: 12-Aug-1996 #sequence\_revision 12-Aug-1996 #text\_change 09-Jul-2004  
C/Accession: I69202  
R:Nomura, H.; Nielsen, B.W.; Matsushima, K.  
Int. Immunol. 5, 1239-1249, 1993  
A>Title: Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemokine (C-C) re  
A/Reference number: I54751; MUID:94092629; PMID:7505609.  
A/Accession: I69202  
A/Status: preliminary; translated from GB/EMBL/DBJ  
A/Molecule type: mRNA  
A/Residues: 1-387 <RES>  
A/Cross-references: UNIPROT:P49019; GB:D10923; NID:G219866; PIDN:BAA01721.1; PID:G219867  
C/Genetics:  
A/Gene: HM74  
C/Superfamily: G protein-coupled receptor 4

Query Match	95.6%	Score	1990;	DB	2;	Length	387;
Best Local Similarity	95.9%	Pred. No.	3.6e-170;	Mismatches	6;	Indels	0;
Matches	371;	Conservative					
Qy	1	MNRHLLQDHFLEIDKKNCCVFRDDFI	VKVLPPVLGLSEFIFGLLGNGLALMIFCFHLKSWK	60			
Db	1	MNRHLLQDHFLEIDKKNCCVFRDDFI	AKVLPVLGLSEFIFGLLGNGLALMIFCFHLKSWK	60			
Qy	61	SSRIFLNLAVADFLLLIICLPFLMDNVYRRMDWKFGDIPCLRLMFLMLAMNRQGSIIIFLTV	120				
Db	61	SSRIFLNLAVADFLLLIICLPFLMDNVYRRSDWNFGDIPCLRLVLFMFAMNRQGSIIIFLTV	120				
Qy	121	VADRYFRVPHPHALNKISNRTAAIISCLLWGTIGLTVHLKKKPKIONGGANLCSF	180				
Db	121	VADRYFRVPHPHALNKISNRTAAIISCLLWGTIGLTVHLKKKLIIONGPANVCISF	180				
Qy	181	SICHTFOWHEAMFLLEPFLPLGIILFCSARIINSLRQMDRQMDRAKIKRAITFIWVAIVF	240				
Db	181	SICHTFOWHEAMFLLEPFLPLGIILFCSARIINSLRQMDRQMDRAKIKRAITFIWVAIVF	240				
Qy	241	VICFLPSVVVRIIRIFLLWLTSGTQNCBVYRSVDLAFFITLSFTYMNMLDPVVVYFSSPS	300				
Db	241	VICFLPSVVVRIIRIFLLWLTSGTQNCBVYRSVDLAFFITLSFTYMNMLDPVVVYFSSPS	300				
Qy	301	FPNFFSTLIINRCLOKMKTEPDNNRSTSVELTGDPNKTRGAPEALMANSCEPWPSPSYLGP	360				
Db	301	FPNFFSTLIINRCLOKMKTEPDNNRSTSVELTGDPNKTRGAPEALMANSCEPWPSPSYLGP	360				
Qy	361	TSNNHKKGHCHOBPASLEKOLGCCIE	387				
Db	361	TSNNHKKGHCHOBPASLEKOLGCCIE	387				

## RESULT 2

S33733  
G protein-coupled receptor - chicken  
C:Species: Gallus gallus (chicken)  
C:Date: 06-Jan-1995 #sequence\_revision 06-Jan-1995 #text\_change 09-Jul-2004  
C:Accession: S33733  
R:Webb, T.B.; Simon, J.; Krishek, B.J.; Bateson, A.N.; Smart, T.G.; King, B.F.; Burnstock  
FEBS Lett. 324, 219-225, 1993  
A:Title: Cloning and functional expression of a brain G-protein-coupled ATP receptor.  
A:Reference number: S33733; MUID:93285340; PMID:8508924  
A:Accession: S33733  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-362 <WEB>  
A:Cross-references: UNIPROT:P34996; EMBL:X73268; NID:g935084; PIDN:CAA51716.1; PID:g9350  
C:Superfamily: ATP receptor P2u  
C:Keywords: G protein-coupled receptor; transmembrane protein

Query Match	20.7%;	Score 431;	DB 2;	Length 362;
Best Local Similarity	30.7%;	Pred. No. 7.9e-31;		
Matches	101;	Conservative 68;	Mismatches 134;	Indels 26; Gaps 7;

  

Qy	18	CCVFRDPIVKVLPVLGLEPIFGLGLGGLALWIFCFHLKSKSKSRIFLEFLNAVADFLLI	77
Db	31	CSLTKTGFQFYLTIVILVITTFGLGNSVAIMFVFHMRPWSGISVYMFNLALADFLV	90
Qy	78	ICLPFLMDNYVRRWDKFGDIPCLRMFLMLAMNRQGSIFLTVAVDTRYFVWPHPHALN	137
Db	91	LTLPALIFYFNKTDWIFGDVWCKLQRFIFHVNLYGSLFLTCTSVHRYTGVVHPLKSLG	150
Qy	138	KISNRTAAITSCLLWGTTIGTVHLL-----KKMPTONGAN--LCSSP--STCH	184
Db	151	RLKKNAVYVSSLLWALVAVIAPILFYSGTGVRRNKTTTCYDTTADAYLSRYFYVSMCT	210
Qy	185	TFQWHEAMFLEFPFLPGIILFCSARIINWSRQOMDBHAKIKRAITFMVVAIVFVICF	244
Db	211	T-----VFMFCTPIFVLGCGYLVKALYIKDLONSPLRRKSIYLVILTVLTVFVASY	262
Qy	245	LPSVVVR-IRIFWLLHTSGTQNCVEYRSVDLFAFFITLSFTYMNKMLDPVWYFFSSPSPN	303
Db	263	LPFHVMKTLNLRALDFQTPQWCAFNQKVYATYQVTRGLASINCSVDPIILFLAGDTFPR	322
Qy	304	FFSTLINRCLQRKMTGBPDNNRSTSVELT	332
Db	323	RLSRATRKSGRR---SEP-NVOCSEEMT	347

RESIST 3

RESOLU\_3  
 JC4162  
 P2Y receptor - bovine  
 C;Species: Bos primigenius taurus (cattle)  
 C;Date: 12-Oct-1995 #sequence\_revision 10-Nov-1995 #text\_change 09-Jul-2004  
 C;Accession: JC4162  
 R;Henderson, D.J.; Elliot, D.G.; Smith, G.M.; Webb, T.E.; Dainty, I.A.  
 Biochem. Biophys. Res. Commun. 212, 648-656, 1995  
 A;Title: Cloning and characterisation of a bovine P2Y receptor.  
 A;Reference number: dC4162; MUID:95352058; PMID:7626079  
 A;Accession: JC4162  
 A;Molecule type: mRNA  
 A;Residues: 1-373 <HEN>  
 A;Cross-references: UNIPROT:P48042; EMBL:X87628; NID:g1032484; PIDN:CAA60958.1; PID:g1032484  
 A;Experimental source: aortic endothelial cell  
 C;Genetics:  
 A;Gene: bovp2y  
 C;Superfamily: ATP receptor P2u  
 C;Keywords: glycoprotein; phosphoprotein; receptor; transmembrane protein  
 F;52-77/Domain: transmembrane #status predicted <TM1>  
 F;88-111/Domain: transmembrane #status predicted <TM2>  
 F;124-150/Domain: transmembrane #status predicted <TM3>  
 F;171-191/Domain: transmembrane #status predicted <TM4>  
 F;214-237/Domain: transmembrane #status predicted <TM5>  
 F;261-282/Domain: transmembrane #status predicted <TM6>  
 F;305-328/Domain: transmembrane #status predicted <TM7>

F;11,27,113,197/Binding site: carbohydrate (Asn) (covalent) #status predicted  
F;258/Binding site: phosphate (Ser) (covalent) (by protein kinase A) #status predicted

Query Match 19.9%; Score 415; DB 2; Length 373;  
Best Local Similarity 29.8%; Pred. No. 2.2e-29;

## RESULT 4

G protein-coupled receptor P2Y1 - human  
N;Alternate names: P2Y1 purinergic receptor; P2Y1 purinoceptor  
C;Species: Homo sapiens (man)  
C;Date: 10-May-1996 #sequence, revision 16-Aug-1996 #text\_change 09-Jul-2004  
C;Accession: JC4737, JC4615, S54253  
R;Janssens, R.; Communi, D.; Pirotton, S.; Samson, M.; Parmentier, M.; Boeynaems, J. M.  
Biochem. Biophys. Res. Commun. 221, 588-593, 1996  
A;Title: Cloning and tissue distribution of the human P2Y1 receptor.  
A;Reference number: JC4737; MUID:96205320; PMID:8630005













---



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 20, 2005, 05:58:30 ; Search time 59 Seconds  
(without alignments)  
3358.892 Million cell updates/sec

Title: US-10-800-249-2  
Perfect score: 2081.  
Sequence: 1 MNRHLDQHFLEIDKKNCCV.....KGHCHEPASLEKQLGCCIE 387

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : UniProt\_03.\*  
1: uniprot\_sprot.\*  
2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1995	95.9	387	QNGE4	Qnge4 homo sapien
2	1990	95.6	387	G09B_HUMAN	P49019 homo sapien
3	1935	93.0	363	Q8TDS4	Q8tds4 homo sapien
4	1591	76.5	360	Q80Z39	Q80z39 rattus norv
5	1577	75.8	360	Q3EP66	Q3ep66 mus musculu
6	1111	53.4	263	Q8NGV8	Q8ngv8 homo sapien
7	900.5	43.3	343	G081_MOUSE	Q8c131 mus musculu
8	883.5	42.5	346	G081_HUMAN	Q8bxc0 homo sapien
9	876.5	42.1	346	Q6NXU5	Q6nxu5 homo sapien
10	563	27.1	384	Q8NGW4	Q8ngw4 homo sapien
11	563	27.1	384	Q86WP7	Q86wp7 homo sapien
12	563	27.1	423	Q8TDS5	Q8tds5 homo sapien
13	496.5	23.9	319	Q8NQ20	Q8nq20 homo sapien
14	494.5	23.8	319	G031_HUMAN	O00270 homo sapien
15	481	23.1	319	Q3JLS1	Q9jlsl mus musculu
16	431	20.7	362	P2YR_CHICK	P34996 gallus gall
17	431	20.7	362	P2YR_MELGA	P34962 meleagris g
18	420	20.2	373	P2YR_RAT	P34951 rattus norv
19	415.5	20.0	347	Q7ZZA4	Q7zza4 brachydanio
20	415	19.9	361	Q90X57	Q90x57 xenopus lae
21	415	19.9	373	P2YR_BOVIN	P48042 bos taurus
22	413.5	19.9	357	Q9DE05	Q9de05 raja erinac
23	410	19.7	373	P2YR_MOUSE	P49650 mus musculu
24	407	19.6	373	P2YR_HUMAN	P47900 homo sapien
25	407	19.6	373	Q8BMJ5	Q8bmj5 mus musculu
26	406	19.5	373	P2YR_CAVPO	P59902 cavia porce
27	386.5	18.6	349	Q6P852	Q6p852 xenopus tro
28	378.5	18.2	309	G035_HUMAN	Q9hc97 homo sapien
29	376.5	18.1	394	Q6ZMP9	Q6zmp9 homo sapien
30	374.5	18.0	346	CUT2_HUMAN	Q9ns75 homo sapien
31	374	18.0	339	Q6NS65	Q6ns65 mus musculu

32	368	17.7	374	2	O57466	O57466 meleagris g
33	358	17.2	309	1	CLT2_RAT	Q924c9 rattus norv
34	358	17.2	537	1	P2Y8_XENLA	P79928 xenopus lae
35	358	17.2	537	2	Q7ZWQ7	Q7zwq7 xenopus lae
36	354.5	17.0	370	2	Q6NSP5	Q6nsp5 homo sapien
37	353.5	17.0	370	1	P2Y9_HUMAN	Q99677 homo sapien
38	352.5	16.9	345	1	CLT2_PIG	Q95n03 sus scrofa
39	351.5	16.9	308	1	P2Y5_CHICK	P32250 gallus gall
40	350.5	16.8	307	2	Q8BS98	Q8bs98 mus musculu
41	350.5	16.8	364	2	Q68DM8	Q68dm8 homo sapien
42	350.5	16.8	391	1	BRB2_HUMAN	P30411 homo sapien
43	350	16.8	367	1	GP17_HUMAN	Q13304 homo sapien
44	349	16.8	361	1	P2Y4_MOUSE	O9ij57 mus musculu
45	348.5	16.7	370	2	Q8BKX1	Q8bkk1 mus musculu

ALIGNMENTS

RESULT 1

ID	QNGE4	PRELIMINARY;	PRT;	387 AA.
AC	QNGE4;			
DT	01-OCT-2002 (TrEMBLrel. 22, Created)			
DT	01-OCT-2002 (TrEMBLrel. 22, Last sequence update)			
DT	01-JUN-2003 (TrEMBLrel. 24, Last annotation update)			
DE	Seven transmembrane helix receptor.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
OX	NCBI_TaxID:9606;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RA	Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,			
RA	Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;			
RL	Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.			
CC	-1- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).			
CC	-1- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.			
DR	EMBL; AB065865; BAC06083.1; -			
DR	GO; GO:0016021; C:integral to membrane; IEA.			
DR	GO; GO:0045028; F:purinergic nucleotide receptor activity; IEA.			
DR	GO; GO:0004872; F:receptor activity; IEA.			
DR	GO; GO:0001584; F:rhodopsin-like receptor activity; IEA.			
DR	GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.			
DR	InterPro; IPR002286; GPCR_Rhodopsn.			
DR	Pfam; PF00001; 7tm.1; 1.			
DR	PRINTS; PR00237; GPCR_RHODOPSIN.			
DR	PRINTS; PR01157; P2YPURNOCPTR.			
DR	PROSITE; PS00237; G-PROTEIN_RECEP_F1_1; 1.			
DR	PROSITE; PS00262; G-PROTEIN_RECEP_F1_2; 1.			
KW	G-protein coupled receptor; Receptor; Transmembrane.			
SQ	SEQUENCE 387 AA; 44495 MW; 26433C85E85EC81 CRC64;			

Query Match	95.9%	Score 1995;	DB 2;	Length 387;
Best Local Similarity	96.1%;	Pred. No. 7.1e-130;		
Matches 372;	Conservative 6;	Mismatches 9;	Indels 0;	Gaps 0;
Qy	1	MNRHLDQHFLEIDKKNCCVFRDDPIVKVLPVVLGLEFIFGLLGNGLALWIFCFHLKSKW	60	
Db	1	MNRHLDQHFLEIDKKNCCVFRDDPIAKVLPVVLGLEFIFGLLGNGLALWIFCFHLKSKW	60	
Qy	61	SSRIFFENLAVADFLLIICLPFLMDNVRRWDKFGDIPCLRLMFLMLANRQGSIIIFTV	120	
Db	61	SSRIFFENLAVADFLLIICLPFLMDNVRRWDKFGDIPCLRLMFLMFAANRQGSIIIFTV	120	
Qy	121	VAVDRYFRVPHHALNKSINRTAAISCLLWGITGLTVHLHLKKKPIONGNLCSSF	180	
Db	121	VAVDRYFRVPHHALNKSINRTAAISCLLWGITGLTVHLHLKKKLIQNGPANVCISF	180	
Qy	181	SICHTFQWHEAMFLERFFPLGIILFCSARIWSLRQMDRHAKIKRAITFIWVAIVF	240	
Db	181	SICHTFRWHEAMFLERFFPLGIILFCSARIWSLRQMDRHAKIKRAITFIWVAIVF	240	

Qy	241	VICFLPSVVVRIRIFWLLHTSGTQNCVYRSVDLAFITLSTFTYNNMMLDPVVYFSSPS	300
Db	241	VICFLPSVVVRIRIFWLLHTSGTQNCVYRSVDLAFITLSTFTYNNMMLDPVVYFSSPS	300
Qy	301	FNFFSTLINRCLQRKWTGEPDNNRSTVELTGDPNKTRGAPEALMANSGEPWSPSYLGP	360
Db	301	FNFFSTLINRCLQRKWTGEPDNNRSTVELTGDPNKTRGAPEALMANSGEPWSPSYLGP	360
Qy	361	TSNNHKKGHGCHQEPASLEKQLGCCIE	387
Db	361	TSNNHKKGHGCHQEPASLEKQLGCCIE	387

RESULT 2

G09B_HUMAN	STANDARD;	PRT;	387 AA.
AC	P49019;		
DT	01-FEB-1996 (Rel. 33, Created)		
DT	01-FEB-1996 (Rel. 33, Last sequence update)		
DT	25-OCT-2004 (Rel. 45, Last annotation update)		
DE	Probable G protein-coupled receptor GPR109B (G protein-coupled receptor HM74).		
DE	receptor HM74).		
GN	Name=GPR109B; Synonyms=HM74;		
OS	Homo sapiens (Human)		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
OX	NCBI_TaxID:9606;		
RN	[1]		
RP	SEQUENCE FROM N.A.		
RC	TISSUE=Monocytes;		
RX	MEDLINE=94092629; PubMed=7505609;		
RA	Nomura H., Nielsen B.W., Matsushima K.;		
RT	"Molecular cloning of cDNAs encoding a LB78 receptor and putative		
RT	leukocyte chemotactic peptide receptors.";		
RL	Int. Immunol. 5:1239-1249(1993).		
CC	!- FUNCTION: Orphan receptor.		
CC	!- SUBCELLULAR LOCATION: Integral membrane protein.		
CC	!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.		
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration		
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation		
CC	the European Bioinformatics Institute. There are no restrictions on its		
CC	use by non-profit institutions as long as its content is in no way		
CC	modified and this statement is not removed. Usage by and for commercial		
CC	entities requires a license agreement (See <a href="http://www.isb-sib.ch/announce">http://www.isb-sib.ch/announce</a>		
CC	or send an email to <a href="mailto:license@isb-sib.ch">license@isb-sib.ch</a> ).		
CC	EMBL; D10923; BAA01721.1; -		
DR	PIR; I69202; I69202.		
DR	HSP; P34936; I69202.		
DR	Gene; HGNC:16824; GPR109B.		
DR	MIM; 606039; -		
DR	GO; GO:0005887; C:integral to plasma membrane; TAS.		
DR	GO; GO:0004930; F:G-protein coupled receptor activity; TAS.		
DR	GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; TAS.		
DR	InterPro; IPR0002286; GPCR_Rhodopsin.		
DR	InterPro; IPR0002286; P2_puroceptor.		
DR	Pfam; PF00001; 7tm1.1;		
DR	PRINTS; PR00237; GPCRHHODOPSIN.		
DR	PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.		
DR	PROSITE; PS00262; G_PROTEIN_RECEP_F1_2; 1.		
KW	G-protein coupled receptor; Transmembrane.		
FT	DOMAIN 1 28 Extracellular (Potential).		
FT	TRANSMEM 29 50 1 (Potential).		
FT	DOMAIN 51 63 Cytoplasmic (Potential).		
FT	TRANSMEM 64 85 2 (Potential).		
FT	DOMAIN 86 102 Extracellular (Potential).		
FT	TRANSMEM 103 123 3 (Potential).		
FT	DOMAIN 124 142 Cytoplasmic (Potential).		
FT	TRANSMEM 143 163 4 (Potential).		
FT	DOMAIN 164 194 Extracellular (Potential).		
FT	TRANSMEM 195 209 5 (Potential).		

```

[4]
RA  SEQUENCE FROM N.A.
RP  Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA  Teutsumi S., Aburatani H., Asai K., Akiyama Y.;
RL  Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
CC  -1- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).
CC  -1- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.
DR  EMBL; AB083632; BAB89345.1; -.
DR  EMBL; AY148884; AAN71621.1; -.
DR  EMBL; AB065876; BAC06094.1; -.
DR  GO; GO:0016021; C:integral to membrane; IEA.
DR  GO; GO:0045028; F:purinergic nucleotide receptor activity, G- . . .; IEA.
DR  GO; GO:0004872; F:receptor activity; IEA.
DR  GO; GO:0001584; F:rhodopsin-like receptor activity; IEA.
DR  GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR  InterPro; IPR002286; GPCR_Rhodopsn.
DR  Pfam; PF00001; 7tm_1; 1.
DR  PRINTS; PR00237; GPCR_RHODOPSIN.
DR  PRINTS; PR01157; P2YURNOCPTR.
DR  PROSITE; PS00237; G-PROTEIN_RECEP_F1_1; 1.
DR  PROSITE; PS0262; G-PROTEIN_RECEP_F1_2; 1.
KW  G-protein coupled receptor; Receptor; Transmembrane.
SQ  SEQUENCE 363 AA; 41849 MW; C4B0EE9CC8B1D56 CRC64;

Query Match 93.0%; Score 1935; DB 2; Length 363;
Best Local Similarity 100.0%; Pred. No. 9.3e-126;
Matches 362; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MNRHHQDHELEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLGNGLALWIFCHLKSWK 60
DB 1 MNRHHQDHELEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLGNGLALWIFCHLKSWK 60
QY 61 SSRIFENLAVADFLIIICLPFLMDNYVRRDWKFGDIPCLRLMFLMANNRQSGSIIFLT 120
DB 61 SSRIFENLAVADFLIIICLPFLMDNYVRRDWKFGDIPCLRLMFLMANNRQSGSIIFLT 120
QY 121 VAVDRYFRVPHHALNKISNRATAIISCLLWGITTGLTVHLLKKKMPIONGGANICSSF 180
DB 121 VAVDRYFRVPHHALNKISNRATAIISCLLWGITTGLTVHLLKKKMPIONGGANICSSF 180
QY 181 SICTQWHEAMLEFFELPLGILFCSARIISLRQRODRHAKIKRAITFTMVVAIVF 240
DB 181 SICTQWHEAMLEFFELPLGILFCSARIISLRQRODRHAKIKRAITFTMVVAIVF 240
QY 241 VICFLPSVVVRIIFWLLHSTGTQNCVYRSVDLAFITLSFTYMSMLDPVVVYFSSPS 300
DB 241 VICFLPSVVVRIIFWLLHSTGTQNCVYRSVDLAFITLSFTYMSMLDPVVVYFSSPS 300
QY 301 FPNFFSTLINRCLQKMTGPDNNRSTSVELTGDPNKTRGAPALMANGSPSPSYLGP 360
DB 301 FPNFFSTLINRCLQKMTGPDNNRSTSVELTGDPNKTRGAPALMANGSPSPSYLGP 360
QY 361 TS 362
DB 361 TS 362

RESULT 4
Q80239 PRELIMINARY; PRT; 360 AA.
AC Q80239;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Nicotinic acid receptor.
GN Name=HM74b;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.

[4]
RA  SEQUENCE FROM N.A.
RP  Soga T., Kamhara M., Takasaki J., Matsumoto S., Saito T., Ohishi T.,
RA  Hiyanama H., Matsuo A., Matsushima H., Furuichi K.;
RL  "Molecular identification of nicotinic acid receptor.";
RL  Biochem. Biophys. Res. Commun. 0:0-0(2003).
CC  -1- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).
CC  -1- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.
DR  EMBL; AB103062; BAC58009.1; -.
DR  GO; GO:0016021; C:integral to membrane; IEA.
DR  GO; GO:0004872; F:receptor activity; IEA.
DR  GO; GO:0001584; F:rhodopsin-like receptor activity; IEA.
DR  GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR  InterPro; IPR000276; GPCR_Rhodopsn.
DR  Pfam; PF00001; 7tm_1; 1.
DR  PRINTS; PR00237; GPCR_RHODOPSIN.
DR  PROSITE; PS00237; G-PROTEIN_RECEP_F1_1; 1.
DR  PROSITE; PS0262; G-PROTEIN_RECEP_F1_2; 1.
KW  G-protein coupled receptor; Receptor; Transmembrane.
SQ  SEQUENCE 360 AA; 41458 MW; 975BDEBCA448A6C5 CRC64;

Query Match 76.5%; Score 1591; DB 2; Length 360;
Best Local Similarity 83.7%; Pred. No. 5e-102;
Matches 298; Conservative 18; Mismatches 40; Indels 0; Gaps 0;

QY 7 QDHFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLGNGLALWIFCHLKSWKSSRIFL 66
DB 4 QNHFLVINGKNCCVFRDENIAKVLPPVLGLEFVFLGNGLALWIFCHLKSWKSSRIFL 63
QY 67 ENLAVADFLIIICLPFLMDNYVRRDWKFGDIPCLRLMFLMANNRQSGSIIFLTVAVDY 126
DB 64 ENLAVADFLIIICLPFLTDNYVQVNDWRFSGIFCRVWLFMANNRQSGSIIFLTVAVDY 123
QY 127 FRVVPHPHALNKISNRATAIISCLLWGITTGLTVHLLKKKMPIONGGANICSSFICHTF 186
DB 124 FRVVPHPHALNKISNRATAIISCLLWGITTGLTVHLLYTDMMTRNGDANICSSFICHTF 183
QY 187 QHHEAMLEFFELPLGILFCSARIISLRQRODRHAKIKRAITFTMVVAIVFVICFLP 246
DB 184 RHDAMFLLEFFELPLGILFCSARIISLRQRODRHAKIKRAITFTMVVAIVFVICFLP 243
QY 247 SVVVRIRIFWLLHSTGTQNCVYRSVDLAFITLSFTYMSMLDPVVVYFSSPSFPNFFS 306
DB 244 SVAVRIRIFWLLYKHVNRCDIYSSVDLAFITLSFTYMSMLDPVVVYFSSPSFPNFFS 303
QY 307 TLINRCLQKMTGPDNNRSTSVELTGDPNKTRGAPALMANGSPSPSYLGPTS 362
DB 304 TCINRCLRRKTLGEPDNNRSTSVELTGDPTSIIPGALMTDPSEGPSYLASTS 359

RESULT 5
Q9EP66 PRELIMINARY; PRT; 360 AA.
AC Q9EP66;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Putative seven transmembrane spanning receptor.
GN Name=Gpr109b; Synonyms=Puma-g, Pumag;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=129/SvJ, and C57BL/6;
RA Schaub A., Futterer A., Pfeiffer K.;
RL Submitted (NOV-2000) to the EMBL/GenBank/DBJ databases.
CC -1- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).
DR EMBL; AJ300199; CAC17791.1; -.
DR EMBL; AJ300198; CAC17790.1; -.
DR MGD; MGI:1933383; Gpr109b.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0005525; F:GTP binding; IEA.

```









DR PROSITE; PS00262; G-PROTEIN RECEPTOR; Transmembrane; 384 AA; 41426 MW; 1C8455FED8085F36 CRC64;  
KW G-protein coupled receptor; Receptor; Transmembrane; 384 AA; 41426 MW; 1C8455FED8085F36 CRC64;  
SQ SEQUENCE 384 AA; 41426 MW; 1C8455FED8085F36 CRC64;  
Query Match 27.1%; Score 563; DB 2; Length 384;  
Best Local Similarity 41.8%; Pred. No. 4.7e-31;  
Matches 118; Conservative 52; Mismatches 88; Indels 24; Gaps 5;  
QY 30 LPPVLGLEIFGLGNGLALWIFCHLKSWMKSRIFLNLAVADFLIICLPFLMDNVR 89  
DB 56 LAPILALEFVLGVLGNSLALFICHTRPMTSTNTVFLVSLVAADFLIISNPLRVDYLL 115  
QY 90 RWDKFGDIPCRMLFPLMAMNROGSIIFLTVAVDYRFRVPHHAKLNKISNRTAAIISC 149  
DB 116 HETWRFGAAACKVNLFWLSTNRTASVVFLTAIALNRYLKVQPHVLSRASVGAARVAG 175  
QY 150 LLWGITIGLTVHLLKKMPQNGGANLCSFSI----CHTFQWHEAMFLLEFFLPLGIL 205  
DB 176 GLWVGILLNGHLL-----LSTFGSPCLSRVGTGPSASLRHQALYLLLEFFLPLALIL 230  
QY 206 FCSARIISLRQRMDEHAKIKRAITFIMVVAIVFVICFLPSVV--VRIRIFWLLHTSG 262  
DB 176 GLWVGILLNGHLL-----LSTFGSPCLSRVGTGPSASLRHQALYLLLEFFLPLALIL 230  
QY 231 FAIVSIGLITIRNGLGQAGPQAMRVLMVAVYTICFLPSIIFGWSMVAFWL----- 285  
QY 263 TQCEVRSVDLA---FFITLSFTYMSMLDPVYVYFSSPSF 301  
DB 286 ----SACRSLLDLCQLPHGSLAFTYLSVLDPLVYCFSSPNF 323  
RESULT 11  
Q86WP7 ID Q86WP7 PRELIMINARY; PRT; 384 AA.  
AC Q86WP7; 01-JUN-2003 (TrEMBLrel. 24, Created)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)  
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
DE Putative 5-oxo-ETE G-protein coupled receptor.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22495202; PubMed=12606753;  
RA Jones C.E., Holden S., Tennant L., Bhatia U., Sauwen K., Tranter P.,  
RA Turner J., Kettle R., Bouhelal R., Charlton S., Nirmala N., Jazai G.,  
RA Finan P.;  
RT "Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z-  
RT eicosatetraenoic acid receptor highly expressed on human eosinophils  
RT and neutrophils.";  
RL Mol. Pharmacol. 63:471-477(2003).  
CC -1- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).  
CC -1- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
DR ENBL; AY158687; AAQ17739.1; -;  
DR GO; GO:0050648; F:5(S)-hydroperoxy-6E,8Z,11Z,14Z-icosatetra. . ; ISS.  
DR GO; GO:0050647; F:5-hydroxy-6E,8Z,11Z,14Z-icosatetraenoic aci. . ; ISS.  
DR GO; GO:0050646; F:5-oxo-6E,8Z,11Z,14Z-icosatetraenoic acid bi. . ; ISS.  
DR GO; GO:0004930; F:G-protein coupled receptor activity; ISS.  
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . ; ISS.  
DR GO; GO:0030817; P:regulation of camp biosynthesis; ISS.  
DR InterPro; IPR000276; GPCR\_Rhodopsn.  
DR Pfam; PF00001; 7tm.1; 1.  
DR PRINTS; PR00237; GPCRHDOPSN.  
DR PROSITE; PS00237; G-PROTEIN RECEPTOR; Transmembrane.  
DR PROSITE; PS00262; G-PROTEIN RECEPTOR; Transmembrane.  
KW G-protein coupled receptor; Receptor; Transmembrane.  
SQ SEQUENCE 384 AA; 41412 MW; 0C5E35FED8085F36 CRC64;  
Query Match 27.1%; Score 563; DB 2; Length 384;  
Best Local Similarity 41.8%; Pred. No. 4.7e-31;  
Matches 118; Conservative 52; Mismatches 88; Indels 24; Gaps 5;  
QY 30 LPPVLGLEIFGLGNGLALWIFCHLKSWMKSRIFLNLAVADFLIICLPFLMDNVR 89

DB 56 LAPILALEFVLGVLGNSLALFICHTRPMTSTNTVFLVSLVAADFLIISNPLRVDYLL 115  
QY 90 RWDKFGDIPCRMLFPLMAMNROGSIIFLTVAVDYRFRVPHHAKLNKISNRTAAIISC 149  
DB 116 HETWRFGAAACKVNLFWLSTNRTASVVFLTAIALNRYLKVQPHVLSRASVGAARVAG 175  
QY 150 LLWGITIGLTVHLLKKMPQNGGANLCSFSI----CHTFQWHEAMFLLEFFLPLGIL 205  
DB 176 GLWVGILLNGHLL-----LSTFGSPCLSRVGTGPSASLRHQALYLLLEFFLPLALIL 230  
QY 206 FCSARIISLRQRMDEHAKIKRAITFIMVVAIVFVICFLPSVV--VRIRIFWLLHTSG 262  
DB 231 FAIVSIGLITIRNGLGQAGPQAMRVLMVAVYTICFLPSIIFGWSMVAFWL----- 285  
QY 263 TQCEVRSVDLA---FFITLSFTYMSMLDPVYVYFSSPSF 301  
DB 286 ----SACRSLLDLCQLPHGSLAFTYLSVLDPLVYCFSSPNF 323  
RESULT 12  
Q8TDS5 ID Q8TDS5 PRELIMINARY; PRT; 423 AA.  
AC Q8TDS5; 01-JUN-2002 (TrEMBLrel. 21, Created)  
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)  
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)  
DE G-protein coupled receptor TG1019.  
DE Name-GPCR; Synonyms=OXER1, tg1019;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Takeda S., Kadowaki S., Haga T., Takaesu H., Mitaku S.;  
RL Submitted (Apr-2002) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22191290; PubMed=12065583; DOI=10.1074/jbc.M203194200;  
RA Hosoi T., Koguchi Y., Sugikawa E., Chikada A., Ogawa K., Tsuda N.,  
RA Suto N., Tsunoda S., Taniguchi T., Ohnuki T.;  
RT "Identification of a Novel Human Eicosanoid Receptor Coupled to  
RT G1/o.";  
RL J. Biol. Chem. 277:31459-31465(2002).  
RN [3]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Skin.  
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,  
RA Datchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Raha S.A., Loquellano N.A., Peters G.J., Abramson R.D., Mullah S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalon D.K., Muzny K.C., Hale S., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahy J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.C., Dickinson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,  
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,  
RA Jones S.J., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length human  
RT and mouse cDNA sequences.";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [4]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Skin;  
RA Strausberg R.;







This Page Blank (uspto)

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 20, 2005, 05:56:35 ; Search time 68 Seconds  
(without alignments)  
2201.122 Million cell updates/sec

Title: US-10-800-249-2  
Perfect score: 2081.  
Sequence: 1 MNRHHLDHFLDKKNCVV.....KGCHQBPASLEKQLGCCIE 387

Scoring table: BLOSUM62  
Gapop 10.0 ; Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A Geneseq\_16Dec04:.\*  
1: geneseqp1980s:.\*  
2: geneseqp1990s:.\*  
3: geneseqp2000s:.\*  
4: geneseqp2001s:.\*  
5: geneseqp2002s:.\*  
6: geneseqp2003as:.\*  
7: geneseqp2003bs:.\*  
8: geneseqp2004s:.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES.

Result No.	Score	Query Match %	Length	DB ID	Description
1	2081	100.0	387	8	ADT08043 Human G-p
2	1996	95.9	387	5	AAU77992 Human inf
3	1996	95.9	387	5	ADJ63768 Human G p
4	1996	95.9	387	7	ADF28984 Human G p
5	1995	95.9	387	6	ABR48195 Human bla
6	1995	95.9	387	7	ADN38906 Cancer/an
7	1995	95.9	387	8	ADQ60130 Human G-p
8	1995	95.9	625	7	ADF70463 Orphan re
9	1990	95.6	387	3	AAU90637 Human G p
10	1990	95.6	387	5	ABP54318 Human G p
11	1990	95.6	387	5	ABB98163 Human HM7
12	1990	95.6	387	5	AAU79041 Human G p
13	1990	95.6	387	6	ABP81898 Human G p
14	1990	95.6	387	7	ADH14100 Human HM7
15	1990	95.6	387	7	ADH117891 Human HM7
16	1990	95.6	387	7	ADN38910 Cancer/an
17	1990	95.6	387	7	ADN01996 Human inf
18	1990	95.6	387	8	ADO29488 Human GPC
19	1990	95.6	387	8	ADO59893 Human HM-
20	1990	95.6	387	8	ADO32541 hRUP38 re
21	1990	95.6	387	8	ADR43757 Human HM7
22	1990	95.6	387	8	ADP23835 PRO polyp
23	1990	95.6	387	8	ADG17050 Human 311
24	1990	95.6	387	8	ADT08044 Human G-p
25	1990	95.6	387	8	ADT08044 Human G-p

26	1988	95.5	387	3	AAU90672 Human mut
27	1988	95.5	387	7	ADC22741 Human G p
28	1988	95.5	387	7	ADH14214 Mucated h
29	1988	95.5	387	8	ADM46114 Human S-o
30	1935	93.0	362	6	ABG72358 Human orp
31	1935	93.0	363	2	AAW94654 G-protein
32	1935	93.0	363	4	AAU04379 Human G-p
33	1935	93.0	363	7	ADC86215 Human GPC
34	1935	93.0	363	7	ADL96482 Human G p
35	1935	93.0	363	7	ADN38908 Cancer/an
36	1935	93.0	363	8	ADM46118 Human S-o
37	1935	93.0	363	8	ADN41887 Amino aci
38	1935	93.0	363	8	ADO05575 Human hRU
39	1935	93.0	363	8	ADP04973 Human HM7
40	1935	93.0	363	8	ADO32543 hRUP25 re
41	1935	93.0	363	8	ADR37504 Human HM7
42	1930	92.7	363	5	AAU77993 Human inf
43	1930	92.7	363	5	ADJ63782 Human G p
44	1930	92.7	363	7	ADF28998 Human G p
45	1918.5	92.2	362	8	ADT08045 Human GPC

## ALIGNMENTS

RESULT 1  
ADT08043  
ID ADT08043 standard; protein; 387 AA.

XX AC ADT08043;  
XX DT 16-DEC-2004 (first entry)  
XX DE Human G-protein coupled receptor HGRPRMY74, SEQ ID 2.

XX KW GPCR; HGRPRMY74; G-protein coupled receptor; immunosuppressive;  
XX KW antilipaseic; antidiabetic; anorectic; antiinflammatory; cardiant;  
XX KW antirheumatic; antiarthritic; antiarteriosclerotic; osteopathic;  
XX KW pulmonary; antialthmatic; cyostatic; dermatological; antipsoriatic;  
XX KW ophthalmological; human; receptor.

XX OS Homo sapiens.

Key	Location/Qualifiers
FT Domain	38..54
FT Domain	/note = transmembrane domain TM1
FT Domain	64..84
FT Domain	/note = transmembrane domain TM2
FT Domain	95..123
FT Domain	/note = transmembrane domain TM3
FT Domain	144..163
FT Domain	/note = transmembrane domain TM4
FT Domain	191..209
FT Domain	/note = transmembrane domain TM5
FT Domain	229..250
FT Domain	/note = transmembrane domain TM6
FT Domain	274..292
FT Domain	/note = transmembrane domain TM7

WO2004083388-A2.

30-SEP-2004.

12-MAR-2004; 2004WO-US007618.

14-MAR-2003; 2003US-0454942P.

(BRIM ) BRISTOL-MYERS SQUIBB CO.

Ramanathan CS, Feder JN;

WPI; 2004-691038/67.

N-PSDB; ADT08042.

XX New nucleic acid molecules encoding HGRPMY74 polypeptides of the G-  
PT protein coupled receptor superfamily, useful for diagnosing, treating, or  
PT ameliorating dyslipidaemia, diabetes, or inflammatory disorders.  
XX  
XX  
XX Claim 5; Fig 1A-B; 332pp; English.  
XX  
XX The invention relates to an isolated human G-protein coupled receptor  
CC (GPCR), HGRPMY74 and encoding polynucleotides. The HGRPMY74 polypeptide  
CC can be expressed by standard recombinant methodology. The nucleic acid  
CC molecules, polypeptides, modulators and methods are useful for  
CC diagnosing, treating or ameliorating a pathological condition, e.g. a  
CC disorder related to aberrant G-protein coupled signaling; a disorder  
CC related to aberrant nicotinic acid dependent-G-protein coupled signaling;  
CC a disorder related to aberrant cell cycle regulation; cardiovascular  
CC disorders; an immune disorder; disorders associated with aberrant  
CC nicotinic acid utilization; disorders associated with aberrant nicotinic  
CC acid absorption; disorders associated with aberrant in nicotinic acid  
CC responses; dyslipidaemia; diabetic dyslipidaemia; mixed dyslipidaemia;  
CC hypercholesterolemia; hypertriglyceridemia; type II diabetes mellitus; type  
CC I diabetes; insulin resistance; hyperlipidaemia; obesity; anorexia  
CC nervosa; disease or disorders known to be associated with HM74; disease  
CC or disorders known to be associated with HM74A; heart failure;  
CC atherosclerosis; arteriosclerosis; hypertriglyceridemia; inflammatory  
CC disorders; arthritis; rheumatoid arthritis; osteoarthritis; prosthetic  
CC joint failure; gastrointestinal tract disorders; ulcerative colitis;  
CC Crohn's disease; inflammatory bowel disorder; gastritis; mucosal  
CC inflammation; enteropathy provoked by non-steroidal anti-inflammatory  
CC drugs; lung disorders; adult respiratory distress syndrome; asthma;  
CC cystic fibrosis; chronic obstructive pulmonary disease; myocardiitis;  
CC multiple sclerosis; inflammation associated with diabetes mellitus;  
CC glomerulonephritis; dermatitis; psoriasis; eczema; urticaria; burn injury  
CC ; glaucoma; organ rejection; systemic lupus erythematosus; sepsis;  
CC ischaemic heart disease; disorders associated with aberrant lipolysis;  
CC stroke; dyslipidaemia; disorders associated with below average levels of  
CC high density lipoprotein (HDL); disorders associated with above average  
CC levels of very low density lipoprotein (VLDL); disorders associated with  
CC above average levels of low density lipoprotein (LDL); and disorders  
CC associated with above average levels of cholesterol. The present sequence  
CC represents a human GPCR, HGRPMY74.  
XX  
XX Sequence 387 AA;

Query Match 100.0%; Score 2081; DB 8; Length 387;  
Best Local Similarity 100.0%; Pred. No. 6.1e-207;  
Matches 387; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVGLGFIPLGLNGLALWIFCFHLKSWK 60  
DB 1 MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVGLGFIPLGLNGLALWIFCFHLKSWK 60  
QY 61 SSRIFLNLAVADFLIIICLPFLMDNYYRRWDKFGDIPCRMLFMLAMNRQGSIIFLT 120  
DB 61 SSRIFLNLAVADFLIIICLPFLMDNYYRRWDKFGDIPCRMLFMLAMNRQGSIIFLT 120  
QY 121 VAVDRFVVVPHHAIKNSRTAAIISCLLWGITITGLTVHLKXKQPTONGANICSSF 180  
DB 121 VAVDRFVVVPHHAIKNSRTAAIISCLLWGITITGLTVHLKXKQPTONGANICSSF 180  
QY 181 SICTTQWHEAMFLLFFPLGLIIFCSARIISLQRQNDRAKIKRAITFTMVVAIVF 240  
DB 181 SICTTQWHEAMFLLFFPLGLIIFCSARIISLQRQNDRAKIKRAITFTMVVAIVF 240  
QY 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVRSVDLAFITLSFTYMSMLDPVVYYFSSPS 300  
DB 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVRSVDLAFITLSFTYMSMLDPVVYYFSSPS 300  
QY 301 FPNFSTLINRCLORQWTCGPDNNRSTSVELTGDPNKTRCAPEALMANSCEPSPSYLGP 360  
DB 301 FPNFSTLINRCLORQWTCGPDNNRSTSVELTGDPNKTRCAPEALMANSCEPSPSYLGP 360  
QY 361 TSNNHKKGHCHOEPASLEKQLGCCIE 387  
XX

DB 361 TSNNHKKGHCHOEPASLEKQLGCCIE 387  
RESULT 2  
AAU77992  
XX ID AAU77992 standard; protein; 387 AA.  
XX AC AAU77992;  
XX DT 02-JUL-2002 (first entry)  
XX DE Human inflammation-associated GPCR EX20 polypeptide.  
XX KW Human; inflammation-associated G-protein coupled receptor; GPCR; EX20;  
KW inflammatory disease; asthma; adult respiratory distress syndrome; ARDS;  
KW chronic obstructive pulmonary disease; COPD; bronchitis; emphysema;  
KW pneumoconiosis; neutrophil; eosinophil related disorder; airway;  
KW lung-related disorder; rheumatoid arthritis; inflammatory bowel disease;  
KW ulcerative colitis; skin disease; eczematous dermatitis; receptor.  
XX OS Homo sapiens.  
XX WO200213845-A2.  
XX PN 21-FEB-2002.  
XX PD 16-AUG-2001; 2001WO-EP009466.  
XX PF 18-AUG-2000; 2000US-00641653.  
XX PR (NOVS ) NOVARTIS AG.  
XX PA (NOVS ) NOVARTIS-ERFINDUNGEN VERW GES MBH.  
XX Jari G, Yousefi S;  
XX WPI: 2002-329542/36.  
XX DR N-PSDB; ABK47759.  
XX New pharmaceutical composition comprising EX20 polypeptide, EX20  
PT polynucleotide, antibodies against EX20 polypeptide, antisense  
PT oligonucleotides against EX20 polynucleotide, useful for treating  
PT inflammatory disease.  
XX Claim 2; Page 31-32; 36pp; English.  
XX The present invention relates to human inflammation-associated G-protein  
CC coupled receptor (GPCR) EX20 polypeptide and the polynucleotide sequence  
CC encoding it. A pharmaceutical composition comprising EX20 polypeptide, a  
CC variant of EX20, an antibody which immunoreacts with EX20, a  
CC polynucleotide encoding EX20 or an antisense oligonucleotide comprising a  
CC nucleotide sequence complementary to EX20 can be used in diagnostic and  
CC therapeutic applications for treating an inflammatory disease. Such  
CC inflammatory diseases include asthma, adult respiratory distress syndrome  
CC (ARDS), chronic obstructive pulmonary disease (COPD) including chronic  
CC bronchitis, emphysema, pneumoconiosis, neutrophil or eosinophil related  
CC disorders, airway and lung-related disorders, rheumatoid arthritis, skin  
CC eczematous dermatitis, ulcerative colitis, and skin diseases such as  
CC -associated GPCR EX20 polypeptide  
XX Sequence 387 AA;

Query Match 95.9%; Score 1996; DB 5; Length 387;  
Best Local Similarity 96.1%; Pred. No. 4.1e-198;  
Matches 372; Conservative 6; Mismatches 9; Indels 0; Gaps 0;  
QY 1 MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVGLGFIPLGLNGLALWIFCFHLKSWK 60  
DB 1 MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVGLGFIPLGLNGLALWIFCFHLKSWK 60  
QY 61 SSRIFLNLAVADFLIIICLPFLMDNYYRRWDKFGDIPCRMLFMLAMNRQGSIIFLT 120  
DB 61 SSRIFLNLAVADFLIIICLPFLMDNYYRRWDKFGDIPCRMLFMLAMNRQGSIIFLT 120

QY 121 VAVDRYFRVPHALNKNISNRTAAIISCLLWGITIGLTVHLLKKKMPIONGGANLCSF 180  
DB 121 VAVDRYFRVPHALNKNISNRTAAIISCLLWGITIGLTVHLLKKKLIQNGTANVCISF 180  
QY 181 SICHTFQWHEAMFLEFPLGLIIFCSARIISLROQRMDRHAQIKRAITFIMVVAIVF 240  
DB 181 SICHTFQWHEAMFLEFPLGLIIFCSARIISLROQRMDRHAQIKRAITFIMVVAIVF 240  
QY 241 VICFLPSVVVRIRIFWLLHTSGTQNCVYRSVDLAFITILSFTYMSMLDPVVYFSSPS 300  
DB 241 VICFLPSVVVRIRIFWLLHTSGTQNCVYRSVDLAFITILSFTYMSMLDPVVYFSSPS 300  
QY 301 FPNFFSTLINRCLQKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSVYLGP 360  
DB 301 FPNFFSTLINRCLQKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSVYLGP 360  
QY 361 TSNNHKKKGCHQEPASLEKQGCCIE 387  
DB 361 TSNNHKKKGCHQEPASLEKQGCCIE 387

## RESULT 3

ADJ63768  
ID ADJ63768 standard; protein; 387 AA.

XX AC ADJ63768;

XX DT 20-MAY-2004 (first entry)

XX DE Human G protein-coupled receptor EX20 #1.

XX KW Human; receptor; G protein-coupled receptor; EX20; GPCR;  
XX KW inflammatory disease; obstructive airway disease; asthma;  
XX KW chronic obstructive pulmonary disease; neutrophil related disorder;  
XX KW eosinophil related disorder; inflammatory skin disease;  
XX KW eczematous dermatitis.

XX OS Homo sapiens.

XX PN US2004038895-A1.

XX PD 26-FEB-2004.

XX PF 14-JUL-2003; 2003US-00619141.

XX PR 18-AUG-2000; 2000US-00641653.

XX PR 18-AUG-2000; 2000US-0421154P.

XX PR 15-AUG-2001; 2001US-00930334.

XX PA (JARA/) JARAI G.

XX PA (YOUS/) YOUSEFI S.

XX PI Jarai G, Yousefi S;

XX DR WPI; 2002-329542/36.

XX DR N-PSDB; ADJ63767.

XX PT New pharmaceutical composition comprising EX20 polypeptide, EX20

XX PT polynucleotide, antibodies against EX20 polypeptide, antisense

XX PT oligonucleotides against EX20 polynucleotide, useful for treating

XX PT inflammatory disease.

XX PS Claim 1; SEQ ID NO 2; 17pp; English.

XX CC The invention relates to a pharmaceutical composition, comprising an  
XX CC inflammation-associated G protein-coupled receptor (GPCR) gene designated  
XX CC EX20 (e.g. the cDNAs appearing as ADJ63767 or ADJ63781, EX20 polypeptide  
XX CC (appearing as ADJ63768 and ADJ63782, an anti-EX20 antibody or an  
XX CC antisense oligonucleotide against EX20 expression. Also included are an  
XX CC antibody which is immunoreactive with a polypeptide, an antisense  
XX CC oligonucleotide comprising a nucleotide sequence complementary to that of  
XX CC the polynucleotide, a polynucleotide probe comprising at least 15

CC contiguous nucleotides of the polynucleotide or its complement, a method  
CC of treating an inflammatory disease, a method of detecting the presence  
CC of a polynucleotide in a cell or tissue, a method of determining whether  
CC a subject has an inflammatory disease, a method of monitoring treatment  
CC of a subject having an inflammatory disease, a pair of oligonucleotides  
CC useful as primers for amplification of a fragment of the polynucleotide  
CC (each oligonucleotide of the pair is at least 15 nucleotides in length  
CC and the pair having sequences so that when used in a polymerase chain  
CC reaction with human genomic DNA or a suitable human cDNA target, they  
CC result in synthesis of a DNA fragment containing a part or all of the  
CC nucleotide sequence of the polynucleotide) and a method of identifying a  
CC substance suitable for use in the treatment of an inflammatory disease.  
CC Treating an inflammatory disease comprises administering to a subject an  
CC amount of the polypeptide, polynucleotide, antibody or antisense  
CC oligonucleotide (the disease is an inflammatory or obstructive airway  
CC disease, preferably asthma or chronic obstructive pulmonary disease). The  
CC polypeptide, polynucleotide, antibody or antisense oligonucleotide is  
CC useful for the preparation of a medicament for the treatment of  
CC inflammatory diseases. It is also useful for treating neutrophil or  
CC eosinophil related disorders and inflammatory skin diseases including  
CC eczematous dermatitis. The present sequence represents EX20.

XX SQ Sequence 387 AA;

Query Match 95.9%; Score 1996; DB 5; Length 387;

Best Local Similarity 96.1%; Pred. No. 4.1e-198;

Matches 372; Conservative 6; Mismatches 9; Indels 0; Gaps 0;

QY 1 MNRHHLDHFLEIDKKNCCVFRDDFIVKVLPPVGLGFIFGLLGNGLALMIFCFHLKSWK 60

DB 1 MNRHHLDHFLEIDKKNCCVFRDDFIAKVLPPVGLGFIFGLLGNGLALMIFCFHLKSWK 60

QY 61 SSRIFLNLAVADFLIICLPFLMDNVYRWDWKFGDIPCLRLMFLMAMNRQGSIIFLT 120

DB 61 SSRIFLNLAVADFLIICLPFVMDYVRRSDMKFGDIPCLRLVLFPMAMNRQGSIIFLT 120

QY 121 VAVDRYFRVPHALNKNISNRTAAIISCLLWGITIGLTVHLLKKKMPIONGGANLCSF 180

DB 121 VAVDRYFRVPHALNKNISNRTAAIISCLLWGITIGLTVHLLKKKLIQNGTANVCISF 180

QY 181 SICHTFQWHEAMFLEFPLGLIIFCSARIISLROQRMDRHAQIKRAITFIMVVAIVF 240

DB 181 SICHTFQWHEAMFLEFPLGLIIFCSARIISLROQRMDRHAQIKRAITFIMVVAIVF 240

QY 241 VICFLPSVVVRIRIFWLLHTSGTQNCVYRSVDLAFITILSFTYMSMLDPVVYFSSPS 300

DB 241 VICFLPSVVVRIRIFWLLHTSGTQNCVYRSVDLAFITILSFTYMSMLDPVVYFSSPS 300

QY 301 FPNFFSTLINRCLQKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSVYLGP 360

DB 301 FPNFFSTLINRCLQKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSVYLGP 360

QY 361 TSNNHKKKGCHQEPASLEKQGCCIE 387

DB 361 TSNNHKKKGCHQEPASLEKQGCCIE 387

## RESULT 4

ADJ28984

ID ADJ28984 standard; protein; 387 AA.

XX AC ADJ28984;

XX DT 12-FEB-2004 (first entry)

XX DE Human G protein-coupled receptor (GPCR) EX20 polypeptide #1.

XX KW Human; G protein-coupled receptor; GPCR; EX20; inflammatory disease;  
XX KW obstructive airways disease; asthma;

XX KW chronic obstructive pulmonary disease; COPD;

XX KW respiratory tract inflammation; bronchitis; emphysema;

XX KW adult respiratory distress syndrome; ARDS; rheumatoid arthritis;

XX KW inflammatory bowel disease; IBD; ulcerative colitis;

KW primary sclerosing cholangitis; Crohn's disease; antiinflammatory;  
 KW antiasthmatic; receptor.  
 OS Homo sapiens.  
 PN US2003078218-A1.  
 XX 24-APR-2003.  
 XX 15-AUG-2001; 2001US-00930334.  
 XX 15-AUG-2001; 2001US-00930334.  
 XX (JARA/) JARAI G.  
 PA (YOUS/) YOUSEFI S.  
 XX Jarai G, Yousefi S;  
 XX WPI; 2003-635083/60.  
 DR N-PSDB; ADP28983.  
 XX New pharmaceutical composition comprising a polypeptide, polynucleotide,  
 PT antibody and/or antisense oligonucleotide, useful for diagnosing and/or  
 PT treating an inflammatory and/or obstructive airways disease.  
 XX Claim 1; SEQ ID NO 2; 18pp; English.  
 XX The invention relates to a pharmaceutical composition comprising active  
 CC ingredients of a human G protein-coupled receptor (GPCR) polypeptide, a  
 CC polynucleotide encoding the polypeptide, an antibody which is  
 CC immunoreactive with the polypeptide or an antisense oligonucleotide  
 CC comprising a nucleotide sequence complementary to the polypeptide. The  
 CC composition is used for treating an inflammatory disease or an  
 CC obstructive airways disease, e.g. asthma, chronic obstructive pulmonary  
 CC disease (COPD), respiratory tract inflammation, bronchitis, emphysema,  
 CC adult respiratory distress syndrome (ARDS), rheumatoid arthritis,  
 CC inflammatory bowel disease (IBD), ulcerative colitis, primary sclerosing  
 CC cholangitis and Crohn's disease. The level of expression of the  
 CC polynucleotide is used for diagnosing and monitoring inflammatory  
 CC disease. The expression and/or activity of the polypeptide is also used  
 CC for monitoring inflammatory disease and for screening of substrates  
 CC useful for treating inflammatory disease. This sequence represents a  
 CC human GPCR polypeptide, EX20.  
 XX Sequence 387 AA;  
 SQ  
 Query Match 95.9%; Score 1996; DB 7; Length 387;  
 Best Local Similarity 96.1%; Pred. No. 4.1e-198;  
 Matches 372; Conservative 6; Mismatches 9; Indels 0; Gaps 0;  
 QY 1 MNRHHLDHFLEIDKKNCCVFRDDFTVKVLPVVLGLEFIFGLGNGLALWIFCFHLKSWK 60  
 DB 1 MNRHHLDHFLEIDKKNCCVFRDDFTAKVLPVVLGLEFIFGLGNGLALWIFCFHLKSWK 60  
 QY 61 SSRIFLNLAVADFLIICLPFLMDNVVRRWDKFGDIPCRMLMFLAMNRQGSIIFLT 120  
 DB 61 SSRIFLNLAVADFLIICLPFLMDNVVRRWDKFGDIPCRMLMFLAMNRQGSIIFLT 120  
 QY 121 VAVDRYFRVVPVHPHALNKSINRTAAIISCLLWGITTGLTVHLLKKOMPIONGGANICSSF 180  
 DB 121 VAVDRYFRVVPVHPHALNKSINRTAAIISCLLWGITTGLTVHLLKKOMPIONGGANICSSF 180  
 QY 181 SICTHFWHEAMELLEFFPLGLIILCSARIINSLRQQRMDHAKIKRAITFMVVAIVF 240  
 DB 181 SICTHFWHEAMELLEFFPLGLIILCSARIINSLRQQRMDHAKIKRAITFMVVAIVF 240  
 QY 241 VICFLSVVVRIRIFWLLHTSGTQNCVEYRSVDLAFITLSFTYMSMLDPVVYYFSSPS 300  
 DB 241 VICFLSVVVRIRIFWLLHTSGTQNCVEYRSVDLAFITLSFTYMSMLDPVVYYFSSPS 300  
 QY 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPALMANSCEPWSYILGP 360  
 DB 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPALMANSCEPWSYILGP 360

QY 361 TSNHSHKKGCHQOEPASLEKQLGCCIE 387  
 DB 361 TSNHSHKKGCHQOEPASLEKQLGCCIE 387  
 RESULT 5  
 ABR48195  
 ID ABR48195 standard; protein; 387 AA.  
 XX ABR48195;  
 XX 12-JUN-2003 (first entry)  
 XX Human bladder cancer associated protein sequence SEQ ID NO:108.  
 DE Human; bladder cancer; cytostatic; gene therapy; vaccine.  
 XX Homo sapiens.  
 OS WO2003003906-A2.  
 XX 16-JAN-2003.  
 XX 03-JUL-2002; 2002WO-US021338.  
 XX 03-JUL-2001; 2001US-0302814P.  
 PR 03-AUG-2001; 2001US-0310099P.  
 PR 08-NOV-2001; 2001US-0343705P.  
 PR 13-NOV-2001; 2001US-0350666P.  
 PR 12-APR-2002; 2002US-0372246P.  
 XX (EOSB-) EOS BIOTECHNOLOGY INC.  
 PA Mack DH, Aziz N;  
 PI WPI; 2003-201532/19.  
 DR N-PSDB; ACC51008.  
 XX Detecting a bladder cancer-associated transcript in a cell from a  
 PT patient, comprises contacting a biological sample from the patient with a  
 PT bladder cancer-associated polynucleotide or antibody.  
 XX Claim 10; Page 269; 307pp; English.  
 XX The present invention describes a method for detecting a bladder cancer-  
 CC associated transcript in a cell from a patient. The method comprises  
 CC contacting a biological sample from the patient with a polynucleotide  
 CC that selectively hybridizes to a sequence that is 80 % identical to a  
 CC table of sequences (see ACC50951 to ACC51059). ACC50951 to ACC51059  
 CC encode the human bladder cancer-associated proteins given in ABR48146 to  
 CC ABR48242). Bladder cancer-associated sequences from the present invention  
 CC have cytostatic activities, and can be used in antisense gene therapy and  
 CC in vaccine production. The method can be used for detecting a bladder  
 CC cancer-associated transcript in a cell from a patient. The method is  
 CC useful in diagnosing or treating bladder cancer and in screening for  
 CC compounds that modulate bladder cancer, such as hormones or antibodies.  
 CC The nucleic acid molecules from the present invention may be used in  
 CC various screening and diagnostic methods, and for gene therapy, vaccine  
 CC and/or antisense/inhibition applications  
 XX Sequence 387 AA;  
 SQ  
 Query Match 95.9%; Score 1995; DB 6; Length 387;  
 Best Local Similarity 96.1%; Pred. No. 5.2e-198;  
 Matches 372; Conservative 6; Mismatches 9; Indels 0; Gaps 0;  
 QY 1 MNRHHLDHFLEIDKKNCCVFRDDFTVKVLPVVLGLEFIFGLGNGLALWIFCFHLKSWK 60  
 DB 1 MNRHHLDHFLEIDKKNCCVFRDDFTAKVLPVVLGLEFIFGLGNGLALWIFCFHLKSWK 60  
 QY 61 SSRIFLNLAVADFLIICLPFLMDNVVRRWDKFGDIPCRMLMFLAMNRQGSIIFLT 120  
 DB 61 SSRIFLNLAVADFLIICLPFLMDNVVRRWDKFGDIPCRMLMFLAMNRQGSIIFLT 120



Db 61 SSRIFLNLAVALFLLIICLPVMDYVRRSDMKFGDIPCLVLFMFAMNRQGSIIIFLV 120  
 Qy 121 VAVDRYFRVPHHALNKISNRTAAIISCLLWGITIGLTVHLLKKKMPIONGGANLCSF 180  
 Db 121 VAVDRYFRVPHHALNKISNRTAAIISCLLWGITIGLTVHLLKKKLIQNGPANVCISF 180  
 Qy 181 SICHTFQWHEAMFLLEFLPLGIILFCSARIINSRLRQMDRHAHAKIKRAITFIMVVAIVF 240  
 Db 181 SICHTFQWHEAMFLLEFLPLGIILFCSARIINSRLRQMDRHAHAKIKRAITFIMVVAIVF 240  
 Qy 241 VICFLPSVVRIRIFWLLHTSGTQNCVYRSVDLAFFITLSFTYMNMLDPVYVYFSSPS 300  
 Db 241 VICFLPSVVRIRIFWLLHTSGTQNCVYRSVDLAFFITLSFTYMNMLDPVYVYFSSPS 300  
 Qy 301 FPNFFSTLINRCLQRKMTGPDNNRSTSVELTGPDKTRGAPEALMANGSPSPSYLGP 360  
 Db 301 FPNFFSTLINRCLQRKMTGPDNNRSTSVELTGPDKTRGAPEALMANGSPSPSYLGP 360  
 Qy 361 TSNHSHKKGCHQBPASLEKOLGCCIE 387  
 Db 361 TSNHSHKKGCHQBPASLEKOLGCCIE 387

RESULT 6  
 ADN38906  
 ID ADN38906 standard; protein; 387 AA.  
 XX AC ADN38906;  
 XX  
 XX  
 DT 17-JUN-2004 (first entry)  
 XX  
 DE Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:224.  
 XX  
 KW Human; differential expression; cancer; angiogenic disorder;  
 KW fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;  
 KW inflammatory disease; autoimmune disease;  
 KW retinal neovascularisation syndrome; scarring; uterine fibroid;  
 KW detection; diagnosis; prognosis; drug screening; drug targeting;  
 KW wound healing; contraception; cytostatic; cardiant; immunomodulatory;  
 KW vulnary; gene therapy; vaccine.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003042661-A2.  
 XX  
 XX  
 PD 22-MAY-2003.  
 XX  
 PF 13-NOV-2002; 2002WO-US036810.  
 XX  
 PR 13-NOV-2001; 2001US-0350666P.  
 PR 21-NOV-2001; 2001US-0332464P.  
 PR 29-NOV-2001; 2001US-0334393P.  
 PR 03-DEC-2001; 2001US-0335394P.  
 PR 14-DEC-2001; 2001US-0340376P.  
 PR 08-JAN-2002; 2002US-0347211P.  
 PR 10-JAN-2002; 2002US-0347349P.  
 PR 08-FEB-2002; 2002US-0355250P.  
 PR 13-FEB-2002; 2002US-0356714P.  
 PR 20-FEB-2002; 2002US-0359077P.  
 PR 20-MAR-2002; 2002US-0368809P.  
 PR 04-APR-2002; 2002US-0370110P.  
 PR 12-APR-2002; 2002US-0372246P.  
 PR 05-JUN-2002; 2002US-0386614P.  
 PR 16-JUL-2002; 2002US-0396839P.  
 PR 22-JUL-2002; 2002US-0397775P.  
 PR 22-JUL-2002; 2002US-0397845P.  
 PR 09-SEP-2002; 2002US-0409450P.  
 XX  
 PA (EOSB-) EOS BIOTECHNOLOGY INC.  
 XX  
 XX  
 PI Afar D, Aziz N, Ginsburg WM, Gish KC, Glynn R, Hevezi PA;  
 PI Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;  
 XX

DR WPI; 2003-458649/44.  
 XX N-PSDB; ADN38905.  
 PT Determining the presence or absence of a pathological cell in a patient,  
 PT useful for diagnosing, prognosing or treating cancer, comprises detecting  
 PT a nucleic acid in a biological sample.  
 XX  
 PS Claim 12; SEQ ID NO 224; 1385pp; English.  
 XX  
 CC The invention relates to nucleic acids and proteins (ADN38683-ADN40064)  
 CC whose expression is upregulated or downregulated in specific cancers or  
 CC other diseases such as angiogenic or fibrotic disorders, and to methods  
 CC of determining the presence or absence of a pathological cell in a  
 CC patient by detecting a nucleic acid at least 80% identical to those of  
 CC the invention or by detecting a polypeptide of the invention. The  
 CC invention also relates to expression vectors and host cells comprising a  
 CC nucleic acid of the invention; antibodies which specifically bind a  
 CC polypeptide of the invention; use of such antibodies for drug targeting;  
 CC and methods of screening for modulators of activity or expression of the  
 CC polypeptides and nucleic acids. The nucleic acids, polypeptides,  
 CC antibodies and methods are useful for diagnosing, prognosing and treating  
 CC cancer and other conditions such as psoriasis, ischaemia, heart disease,  
 CC atherosclerosis, inflammatory diseases, autoimmune diseases, retinal  
 CC neovascularisation syndromes, scarring and uterine fibroids. They may  
 CC also be useful in wound healing and in contraception. The present  
 CC sequence represents a polypeptide of the invention.  
 XX  
 XX Sequence 387 AA;

Query Match 95.9%; Score 1995; DB 7; Length 387;  
 Best Local Similarity 96.1%; Pred. No. 5.2e-198;  
 Matches 372; Conservative 6; Mismatches 9; Indels 0; Gaps 0;  
 Qy 1 MNRHLLQDHELEIDKKNCCVFRDDFIKVLPPVVLGLEFIFGLGNGLALMIFCFHLKSWK 60  
 Db 1 MNRHLLQDHELEIDKKNCCVFRDDFIKVLPPVVLGLEFIFGLGNGLALMIFCFHLKSWK 60  
 Qy 61 SSRIFLNLAVALFLLIICLPVMDYVRRSDMKFGDIPCLVLFMFAMNRQGSIIIFLV 120  
 Db 61 SSRIFLNLAVALFLLIICLPVMDYVRRSDMKFGDIPCLVLFMFAMNRQGSIIIFLV 120  
 Qy 121 VAVDRYFRVPHHALNKISNRTAAIISCLLWGITIGLTVHLLKKKMPIONGGANLCSF 180  
 Db 121 VAVDRYFRVPHHALNKISNRTAAIISCLLWGITIGLTVHLLKKKLIQNGPANVCISF 180  
 Qy 181 SICHTFQWHEAMFLLEFLPLGIILFCSARIINSRLRQMDRHAHAKIKRAITFIMVVAIVF 240  
 Db 181 SICHTFQWHEAMFLLEFLPLGIILFCSARIINSRLRQMDRHAHAKIKRAITFIMVVAIVF 240  
 Qy 241 VICFLPSVVRIRIFWLLHTSGTQNCVYRSVDLAFFITLSFTYMNMLDPVYVYFSSPS 300  
 Db 241 VICFLPSVVRIRIFWLLHTSGTQNCVYRSVDLAFFITLSFTYMNMLDPVYVYFSSPS 300  
 Qy 301 FPNFFSTLINRCLQRKMTGPDNNRSTSVELTGPDKTRGAPEALMANGSPSPSYLGP 360  
 Db 301 FPNFFSTLINRCLQRKMTGPDNNRSTSVELTGPDKTRGAPEALMANGSPSPSYLGP 360  
 Qy 361 TSNHSHKKGCHQBPASLEKOLGCCIE 387  
 Db 361 TSNHSHKKGCHQBPASLEKOLGCCIE 387

RESULT 7  
 ADQ60130  
 ID ADQ60130 standard; protein; 387 AA.  
 XX AC ADQ60130;  
 XX  
 DT 07-OCT-2004 (first entry)  
 XX  
 DE Human G-protein coupled receptor protein (GPCR) HM74 protein.  
 XX  
 KW G-protein coupled receptor; GPCR ligand binding; N-formyl-L-methionine;

KW antiinflammatory; antiallergic; antirheumatic; antiarthritic;  
 KW osteopathic; dermatological; immunosuppressive; immunodeficiency;  
 KW allergy; rheumatism; osteoarthritis; lupus erythematosus; human; HM74;  
 KW receptor.  
 XX  
 OS Homo sapiens.  
 PN JP2004198202-A.  
 XX  
 PD 15-JUL-2004.  
 XX  
 PF 17-DEC-2002; 2002JP-00365684.  
 XX  
 PR 17-DEC-2002; 2002JP-00365684.  
 XX  
 PA (TAKE ) TAKEDA CHEM IND LTD.  
 XX  
 DR WPI; 2004-513647/49.  
 XX  
 DR N-PSDB; ADQ60131.  
 XX  
 PT Screening compound or its salt that affects binding of ligand of G-  
 PT protein coupled receptor protein (HM74) with HM74, or its partial peptide  
 PT or salt, by using N-formyl-L-methionine.  
 XX  
 PS Claim 1; SEQ ID NO 1; 51pp; Japanese.  
 XX  
 CC The invention relates to a novel method for screening a compound, or its  
 CC salt, that affects the binding of the ligand of G-protein coupled  
 CC receptor (GPCR) HM74, or its partial peptide or salt, by using  
 CC N-formyl-L-methionine, where HM74 has a fully defined sequence as given  
 CC in the specification. The method of the invention has antiinflammatory,  
 CC antiallergic, antirheumatic, antiarthritic, osteopathic, dermatological,  
 CC and immunosuppressive activities and may be useful for treating  
 CC immunodeficiency disorders, such as allergy, rheumatism, osteoarthritis  
 CC or lupus erythematosus. The current sequence is that of the human G-  
 CC protein coupled receptor protein (GPCR) HM74 protein of the invention.  
 XX  
 SQ Sequence 387 AA;  
 Query Match 95.9%; Score 1995; DB 8; Length 387;  
 Best Local Similarity 96.1%; Pred. No. 5.2e-198;  
 Matches 372; Conservative 6; Mismatches 9; Indels 0; Gaps 0;  
 QY 1 MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWK 60  
 DB 1 MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWK 60  
 QY 61 SSRIFLNLAVADFLIIICLPFLMDNYVRRWDKFGDIPCLRLMFLMANNRQGSIIIFLT 120  
 DB 61 SSRIFLNLAVADFLIIICLPFLMDNYVRRWDKFGDIPCLRLVLFMFAMNRQGSIIIFLT 120  
 QY 121 VAVDRYFRVVPHPHALNKISNRATAIISCLLWGITIGTLVHLLKKKMPIONGGANLCSF 180  
 DB 121 VAVDRYFRVVPHPHALNKISNRATAIISCLLWGITIGTLVHLLKKKMPIONGGANLCSF 180  
 QY 181 SICTHTQWHEAMFLLEFFPLGLGIILFCSARIISLQRQDRHAKIKRAITFTIMVAIVF 240  
 DB 181 SICTHTQWHEAMFLLEFFPLGLGIILFCSARIISLQRQDRHAKIKRAITFTIMVAIVF 240  
 QY 241 VICFLPSVVVIRIFWLLHTSGTQNCCEVRSVDLAFITILSFTYMNMSMLDPVVYYFSSPS 300  
 DB 241 VICFLPSVVVIRIFWLLHTSGTQNCCEVRSVDLAFITILSFTYMNMSMLDPVVYYFSSPS 300  
 QY 301 FPNFESTLNRCLQRKWTGPDNNRSTSVELTGDPNKTRGAPALMANGSEPHSPSYLGP 360  
 DB 301 FPNFESTLNRCLQRKWTGPDNNRSTSVELTGDPNKTRGAPALMANGSEPHSPSYLGP 360  
 QY 361 TSNNHKKGHCHQEPASLEKQLGCCIE 387  
 DB 361 TSNNHKKGHCHQEPASLEKQLGCCIE 387

, RESULT 8

ADF70463  
 ID ADF70463 standard; protein; 625 AA.  
 XX  
 AC ADF70463;  
 XX  
 DT 12-FEB-2004 (first entry)  
 XX  
 DE Orphan receptor ligand-related human protein SeqID86.  
 XX  
 KW ligand; orphan receptor protein; fusion protein; fluorescent protein;  
 KW cell expression; green fluorescent protein; GFP; GFP-1; wild-type GFP;  
 KW GFPuv; Enhanced GFP; EGFP; human.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003071272-A1.  
 XX  
 PD 28-AUG-2003.  
 XX  
 PF 21-FEB-2003; 2003WO-JP001901.  
 XX  
 PR 22-FEB-2002; 2002JP-00045728.  
 PR 23-JUL-2002; 2002JP-00213949.  
 PR 11-OCT-2002; 2002JP-00298237.  
 XX  
 PA (TAKE ) TAKEDA CHEM IND LTD.  
 XX  
 PI Hinuma S, Fujii R, Ogi K, Komatsu H, Kawamata Y, Hosoya M;  
 XX  
 DR WPI; 2003-697654/66.  
 XX  
 DR N-PSDB; ADF70565.  
 XX  
 PT Transformation of cells with a fusion protein of an orphan receptor  
 PT protein with a fluorescent protein useful for identification of ligands  
 PT to the orphan receptor.  
 XX  
 PS Disclosure; SEQ ID NO 86; 594pp; Japanese.  
 XX  
 CC This invention relates to a novel method of identifying ligands to an  
 CC orphan receptor protein which comprises transforming cells with DNA  
 CC encoding a fusion protein of the orphan receptor with a fluorescent  
 CC protein, so that the fusion protein is expressed in the cells (or cell  
 CC membranes isolated from them) and contacting the cells with the potential  
 CC ligand to be tested. A suitable fluorescent protein for incorporation in  
 CC the fusion protein is green fluorescent protein (GFP), for example GFP-1,  
 CC wild-type GFP, GFPuv or Enhanced GFP (EGFP). The method is useful for the  
 CC identification of ligands binding to an orphan receptor protein.  
 XX  
 SQ Sequence 625 AA;  
 Query Match 95.9%; Score 1995; DB 7; Length 625;  
 Best Local Similarity 96.1%; Pred. No. 9.8e-198;  
 Matches 372; Conservative 6; Mismatches 9; Indels 0; Gaps 0;  
 QY 1 MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWK 60  
 DB 1 MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWK 60  
 QY 61 SSRIFLNLAVADFLIIICLPFLMDNYVRRWDKFGDIPCLRLMFLMANNRQGSIIIFLT 120  
 DB 61 SSRIFLNLAVADFLIIICLPFLMDNYVRRWDKFGDIPCLRLVLFMFAMNRQGSIIIFLT 120  
 QY 121 VAVDRYFRVVPHPHALNKISNRATAIISCLLWGITIGTLVHLLKKKMPIONGGANLCSF 180  
 DB 121 VAVDRYFRVVPHPHALNKISNRATAIISCLLWGITIGTLVHLLKKKMPIONGGANLCSF 180  
 QY 181 SICTHTQWHEAMFLLEFFPLGLGIILFCSARIISLQRQDRHAKIKRAITFTIMVAIVF 240  
 DB 181 SICTHTQWHEAMFLLEFFPLGLGIILFCSARIISLQRQDRHAKIKRAITFTIMVAIVF 240  
 QY 241 VICFLPSVVVIRIFWLLHTSGTQNCCEVRSVDLAFITILSFTYMNMSMLDPVVYYFSSPS 300  
 DB 241 VICFLPSVVVIRIFWLLHTSGTQNCCEVRSVDLAFITILSFTYMNMSMLDPVVYYFSSPS 300

Qy 301 FPNFSTLINRCLQRKMTGEPDNNRSTSVELTGPDKTRGAPEALMANSGEPSYLG 360  
Db 301 FPNFSTLINRCLQRKMTGEPDNNRSTSVELTGPDKTRGAPEALMANSGEPSYLG 360  
Qy 361 TSNNHKKGHCHQBPASLEKOLGCCIE 387  
Db 361 TSNNHKKGHCHQBPASLEKOLGCCIE 387

RESULT 9  
AA90637  
ID AA90637 standard; protein; 387 AA.  
AC AA90637;  
XX  
DT 21-AUG-2000 (first entry)  
DE Human G protein-coupled receptor HM74.  
XX  
KW G protein-coupled receptor; GPCR; constitutively active;  
KW intracellular loop 3; transmembrane domain 6; drug screening; agonist;  
KW antagonist.  
XX  
OS Homo sapiens.  
XX  
PN WO200022129-A1.  
XX  
PD 20-APR-2000.  
XX  
PF 12-OCT-1999; 99WO-US023938.  
XX  
PR 13-OCT-1998; 98US-00170496.  
XX  
PA (AREN-) ARENA PHARM INC.  
PI Behan DP, Chalmers DT, Liaw CW;  
XX  
DR WPI; 2000-329165/28.  
XX  
DR N-PSDB; AAA30658.

PT Non-endogenous constitutively activated human G protein-coupled  
PT receptors, useful for identifying agonists for use as pharmaceutical  
PT agents.  
PS Example 1; Page 185-187; 341pp; English.  
XX  
CC The invention relates to constitutively active, non-endogenous versions  
CC of endogenous human orphan G protein-coupled receptors (GPCRs, AA90643-  
CC AA90677 and AA90683-Y90687), and to DNA encoding them (AAA30709-A30743  
CC and AAA30775-A30779). The mutant proteins of the invention contain a  
CC mutation in a portion of the protein comprising intracellular loop 3  
CC (IC3) and transmembrane domain 6 (TM6). A non-endogenous amino acid, X,  
CC is substituted for an endogenous residue in IC3 at a position 16 amino  
CC acids N-terminal of an endogenous proline in TM6 to form a sequence X-  
CC (AA)15-Pro. The endogenous amino acid is selected from Lys, His, Arg or  
CC Ala, and is preferably Lys. When the endogenous residue at this position  
CC is Lys, this residue is replaced by His, Arg or preferably Ala. The 15  
CC amino acid stretch between the substituted amino acid and the Pro may be  
CC endogenous, non-endogenous, or a mixture of endogenous and non-endogenous  
CC residues. The constitutively active GPCRs are useful for identifying  
CC agonists, antagonists and partial agonists for use as pharmaceutical  
CC agents. The mutant proteins are also useful in research settings for  
CC elucidating the roles of the receptors in normal and diseased conditions.  
CC Antagonists for a particular GPCR are useful for treating diseases and  
CC disorders associated with that receptor. Because the novel mutant GPCRs  
CC are constitutively active, they can be used directly for screening of  
CC compounds without the need for endogenous ligands. The present sequence  
CC represents a human wild-type GPCR referred to in an exemplification of  
XX the invention  
XX Sequence 387 AA;

Query Match 95.6%; Score 1990; DB 3; Length 387;  
Best Local Similarity 95.9%; Pred. No. 1.7e-197;  
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;  
Qy 1 MNRHHLODHELEIDKKNCCVFRDDFIKVLPPVLGLEFIFGLLGNGLALMIFCFHLKSWK 60  
Db 1 MNRHHLODHELEIDKKNCCVFRDDFIKVLPPVLGLEFIFGLLGNGLALMIFCFHLKSWK 60  
Qy 61 SSRIFLNLAVADFLIICLPFLMDNYYRRWDMKFGDIPCRLLMFLMANNRQGSIIIFLTV 120  
Db 61 SSRIFLNLAVADFLIICLPFLMDNYYRRWDMKFGDIPCRLLMFLMANNRQGSIIIFLTV 120  
Qy 121 VAVDRIFRVVPHHALNKISNRTAAIISCLLWGITITGLTVHLLKKKWPIONGGANLCSF 180  
Db 121 VAVDRIFRVVPHHALNKISNRTAAIISCLLWGITITGLTVHLLKKKWPIONGGANLCSF 180  
Qy 181 SICHTFOWHEAMFLLEFFLPLGILFCSARIINSLROROMDRHAKIKRAITFIMVVAIVF 240  
Db 181 SICHTFOWHEAMFLLEFFLPLGILFCSARIINSLROROMDRHAKIKRAITFIMVVAIVF 240  
Qy 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFFITLSFTYMNMLDPVVVYFSSPS 300  
Db 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFFITLSFTYMNMLDPVVVYFSSPS 300  
Qy 301 FPNFSTLINRCLQRKMTGEPDNNRSTSVELTGPDKTRGAPEALMANSGEPSYLG 360  
Db 301 FPNFSTLINRCLQRKMTGEPDNNRSTSVELTGPDKTRGAPEALMANSGEPSYLG 360  
Qy 361 TSNNHKKGHCHQBPASLEKOLGCCIE 387  
Db 361 TSNNHKKGHCHQBPASLEKOLGCCIE 387

RESULT 10  
ABP54318  
ID ABP54318 standard; protein; 387 AA.  
XX  
XX .AC ABP54318;  
DT 16-JAN-2003 (first entry)  
XX  
DE Human G protein coupled receptor HM74 protein SEQ ID NO:8.  
XX  
KW Human; G protein coupled receptor; GPCR; HGPBMY27; antiinflammatory;  
KW antiinfectivity; pulmonary; cytostatic; nephrotropic; hormonal;  
KW circulatory; gene therapy; inflammatory disorder; reproductive disorder;  
KW pulmonary disorder; cancer; renal disorder; connective tissue disorder;  
KW endocrine disorder.  
XX  
OS Homo sapiens.  
XX  
XX WO200272755-A2.  
XX  
PD 19-SEP-2002.  
XX  
XX 06-MAR-2002; 2002WO-US006796.  
XX  
XX 07-MAR-2001; 2001US-0273808P.  
XX  
XX 27-MAR-2001; 2001US-0278983P.  
XX  
XX (BRIM ) BRISTOL-MYERS SQUIBB CO.  
XX  
XX Ramanathan C, Feder J, Mintier G, Cacace A, Barber L;  
XX  
XX WPI; 2002-657945/70.  
XX  
XX New polynucleotide encoding a human G-protein coupled receptor for  
XX preventing, treating, or ameliorating e.g. an inflammatory, reproductive,  
XX pulmonary, renal connective tissue, or endocrine disorder.  
XX  
XX Disclosure; Fig 2A-B; 356pp; English.  
XX  
XX The present invention describes a human G protein coupled receptor

CC	(GPCR), designated HGRBMY27 (I). (I) has antiinflammatory,	KW	menstrual irregularities; hirsutism; stress incontinence; gene therapy.
CC	antiinfertility, pulmonary, cytostatic, nephrotropic, hormonal and	XX	
CC	circulatory activities, and can be used in gene therapy. (I) or the	OS	Homo sapiens.
CC	protein encoded by it can be used to prevent, treat, or ameliorate a	XX	
CC	medical condition, such as inflammatory disorders, reproductive	FN	WO200194385-A2.
CC	disorders, pulmonary disorders, cancer, renal disorders, connective	XX	
CC	tissue disorders, endocrine disorders, or disorders involving aberrations	PD	13-DEC-2001.
CC	in tubular tissues. They can also be used to diagnose a pathological	XX	
CC	condition or a susceptibility to (I). The protein can be used to screen	PF	05-JUN-2001; 2001WO-EP006380.
CC	for candidate compounds capable of modulating activity of a GPCR	XX	
CC	polypeptide. The present sequence represents a GPCR given in comparison	PR	05-JUN-2000; 2000US-0208912P.
CC	with the HGRBMY27 protein in the exemplification of the present	XX	
CC	invention	PA	(FARB ) BAYER AG.
XX		XX	
SQ	Sequence 387 AA;	PI	Ramakrishnan S;
		XX	
	Query Match 95.6%; Score 1990; DB 5; Length 387;	DR	WPI; 2002-566439/60.
	Best Local Similarity 95.9%; Pred. No. 1.7e-197;	XX	
	Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;	XX	
QY	1 MNRHHLDHFLFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLGNGLALWIFCFHLKSWK 60	PT	New human HM74-like G-protein coupled receptor polypeptide and
DB	1 MNRHHLDHFLFLEIDKKNCCVFRDDFIAKVLPPVLGLEFIFGLGNGLALWIFCFHLKSWK 60	PT	polynucleotide, useful for treating cancer, cardiovascular disease,
		PT	psychotic and neurological disorders, asthma, obesity and inflammation.
QY	61 SSRIFLNLAVADFLLIICLPFLMDNYVRWDKFGDIPCLRLMFLMNNRQGSIIFLT 120	PS	Disclosure; Fig 4; 105pp; English.
DB	61 SSRIFLNLAVADFLLIICLPFLMDNYVRWDKFGDIPCLRLMFLMNNRQGSIIFLT 120	XX	
QY	121 VAVDRYFRVVPVPHALNKISNRTAAIISCLLWGITTGLTVHLLKKXKLLIQNGPANVCISF 180	CC	The invention relates to an isolated HM74-like G-protein coupled receptor
DB	121 VAVDRYFRVVPVPHALNKISNRTAAIISCLLWGITTGLTVHLLKKXKLLIQNGPANVCISF 180	CC	(GPCR) polypeptide. Polypeptides and polynucleotides of the invention are
QY	181 SICTHTQWHEAMFLLEFFPLGLIIFCSARIISLQRQMDRHAQIKRAITFIMVAIVF 240	CC	useful for screening for agents which decrease the activity of HM74-like
DB	181 SICTHTQWHEAMFLLEFFPLGLIIFCSARIISLQRQMDRHAQIKRAITFIMVAIVF 240	CC	GPCR polypeptides. Compositions of the invention are useful for
QY	241 VICFLPSVVVIRIFWLLHTSGTQNCVRSVDLAFITLSFTYMNMSLDPVVYYFSSPS 300	CC	modulating the activity of HM74-like GPCR in a disease including
DB	241 VICFLPSVVVIRIFWLLHTSGTQNCVRSVDLAFITLSFTYMNMSLDPVVYYFSSPS 300	CC	bacterial, fungal, protozoan and viral infection, particularly human
QY	301 FPNFFSTLINRCLQRKWTGEPDNNRSTVELTGDPNKTRGAPALMANSCEPSPSYLGP 360	CC	immunodeficiency viruses, cancer, anorexia, asthma, central nervous
DB	301 FPNFFSTLINRCLQRKWTGEPDNNRSTVELTGDPNKTRGAPALMANSCEPSPSYLGP 360	CC	system disease, cardiovascular disease, hypotension, hypertension,
QY	361 TSNNHKKKGCHQEPASLEKQGCCIE 387	CC	urinary retention, osteoporosis, obesity, ulcer, inflammation, allergy,
DB	361 TSNNHKKKGCHQEPASLEKQGCCIE 387	CC	multiple sclerosis, neurological disorder and dyskinesias such as
		CC	Parkinson's disease, manic depression, and dementia. The HM74-like GPCR
		CC	gene or its portion or product are useful for treating obesity, wasting
		CC	disorders, stroke, osteoarthritis, respiratory problems, type 2 diabetes,
		CC	thrombotic disease, reduced fertility, complications of pregnancy,
		CC	menstrual irregularities, hirsutism and stress incontinence. Polypeptides
		CC	and polynucleotides of the invention may also be used in gene therapy.
		XX	The current sequence represents a human HM74-like GPCR protein
		SQ	Sequence 387 AA;
			Query Match 95.6%; Score 1990; DB 5; Length 387;
			Best Local Similarity 95.9%; Pred. No. 1.7e-197;
			Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;
QY	1 MNRHHLDHFLFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLGNGLALWIFCFHLKSWK 60	QY	1 MNRHHLDHFLFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLGNGLALWIFCFHLKSWK 60
DB	1 MNRHHLDHFLFLEIDKKNCCVFRDDFIAKVLPPVLGLEFIFGLGNGLALWIFCFHLKSWK 60	DB	1 MNRHHLDHFLFLEIDKKNCCVFRDDFIAKVLPPVLGLEFIFGLGNGLALWIFCFHLKSWK 60
QY	61 SSRIFLNLAVADFLLIICLPFLMDNYVRWDKFGDIPCLRLMFLMNNRQGSIIFLT 120	QY	61 SSRIFLNLAVADFLLIICLPFLMDNYVRWDKFGDIPCLRLMFLMNNRQGSIIFLT 120
DB	61 SSRIFLNLAVADFLLIICLPFLMDNYVRWDKFGDIPCLRLMFLMNNRQGSIIFLT 120	DB	61 SSRIFLNLAVADFLLIICLPFLMDNYVRWDKFGDIPCLRLMFLMNNRQGSIIFLT 120
QY	121 VAVDRYFRVVPVPHALNKISNRTAAIISCLLWGITTGLTVHLLKKXKLLIQNGPANVCISF 180	QY	121 VAVDRYFRVVPVPHALNKISNRTAAIISCLLWGITTGLTVHLLKKXKLLIQNGPANVCISF 180
DB	121 VAVDRYFRVVPVPHALNKISNRTAAIISCLLWGITTGLTVHLLKKXKLLIQNGPANVCISF 180	DB	121 VAVDRYFRVVPVPHALNKISNRTAAIISCLLWGITTGLTVHLLKKXKLLIQNGPANVCISF 180
QY	181 SICTHTQWHEAMFLLEFFPLGLIIFCSARIISLQRQMDRHAQIKRAITFIMVAIVF 240	QY	181 SICTHTQWHEAMFLLEFFPLGLIIFCSARIISLQRQMDRHAQIKRAITFIMVAIVF 240
DB	181 SICTHTQWHEAMFLLEFFPLGLIIFCSARIISLQRQMDRHAQIKRAITFIMVAIVF 240	DB	181 SICTHTQWHEAMFLLEFFPLGLIIFCSARIISLQRQMDRHAQIKRAITFIMVAIVF 240
QY	241 VICFLPSVVVIRIFWLLHTSGTQNCVRSVDLAFITLSFTYMNMSLDPVVYYFSSPS 300	QY	241 VICFLPSVVVIRIFWLLHTSGTQNCVRSVDLAFITLSFTYMNMSLDPVVYYFSSPS 300
DB	241 VICFLPSVVVIRIFWLLHTSGTQNCVRSVDLAFITLSFTYMNMSLDPVVYYFSSPS 300	DB	241 VICFLPSVVVIRIFWLLHTSGTQNCVRSVDLAFITLSFTYMNMSLDPVVYYFSSPS 300
QY	301 FPNFFSTLINRCLQRKWTGEPDNNRSTVELTGDPNKTRGAPALMANSCEPSPSYLGP 360	QY	301 FPNFFSTLINRCLQRKWTGEPDNNRSTVELTGDPNKTRGAPALMANSCEPSPSYLGP 360
DB	301 FPNFFSTLINRCLQRKWTGEPDNNRSTVELTGDPNKTRGAPALMANSCEPSPSYLGP 360	DB	301 FPNFFSTLINRCLQRKWTGEPDNNRSTVELTGDPNKTRGAPALMANSCEPSPSYLGP 360
QY	361 TSNNHKKKGCHQEPASLEKQGCCIE 387	QY	361 TSNNHKKKGCHQEPASLEKQGCCIE 387
DB	361 TSNNHKKKGCHQEPASLEKQGCCIE 387	DB	361 TSNNHKKKGCHQEPASLEKQGCCIE 387
RESULT 11			
ABB98163			
ID	ABB98163 standard; protein; 387 AA.		
XX			
AC	ABB98163;		
DT			
XX	05-NOV-2002 (first entry)		
DE	Human HM74-like GPCR protein #2.		
XX			
KW	Human; HM74-like G protein coupled receptor; GPCR; antibacterial;		
KW	fungicide; viricide; protozoacide; analgesic; cytostatic; antiaschmatic;		
KW	hypertensive; hypotensive; antitumoral; cardiatic; osteopathic; anorectic;		
KW	antiulcer; antiallergic; antiinflammatory; neuroprotective; neuroleptic;		
KW	antiparkinsonian; anticonvulsant; nootropic; tranquiliser; animanic;		
KW	antidepressant; antidiabetic; cerebroprotective; antiarthritic;		
KW	antileptenic; gynecological; depilatory; immunomodulator; bacterial;		
KW	fungal; protozoan; viral; infection; human immunodeficiency virus;		
KW	cancer; anorexia; asthma; central nervous system disease;		
KW	cardiovascular disease; hypotension; hypertension; urinary retention;		
KW	osteoporosis; obesity; ulcer; inflammation; allergy; multiple sclerosis;		
KW	neurological disorder; dyskinesia; Parkinson's disease; manic depression;		
KW	dementia; obesity; wasting disorder; stroke; osteoarthritis; respiratory;		
KW	type 2 diabetes; thrombotic disease; reduced fertility; pregnancy;		

Db	361	TSNNHKKGCHQEPASLEKQLGCCIE	387
<p>     </p>			
RESULT 12			
ID	AAU79041	AAU79041 standard; protein; 387 AA.	
XX	AC	AAU79041;	
XX	DT	18-JUN-2002 (first entry)	
XX	DE	Human G protein-coupled receptor, HM74 receptor.	
XX	KW	Human; G protein-coupled; receptor; HM74; ILM receptor;	
KW	KW	macrophage surface receptor; antiinflammatory; pulmonary;	
KW	KW	chronic inflammatory airway disease; chronic bronchitis;	
KW	KW	chronic obstructive pulmonary disease; COPD.	
XX	OS	Homo sapiens.	
XX	PN	WO200218938-A1.	
XX	PD	07-MAR-2002.	
XX	XX		
PF	XX	23-AUG-2001; 2001WO-BP009727.	
XX	PR	01-SEP-2000; 2000GB-00021484.	
PA	(BOEH )	BOEHRINGER INGELHEIM PHARMA KG.	
PI	Jung B, Kraut N, Mueller S, Kistler B, Seither P, Quast K;		
PI	Weith A;		
DR	WPI; 2002-315590/35.		
DR	N-PSDB; ABK48114.		
XX	Determining an expression level of ILM (a macrophage surface receptor),		
PT	for the diagnosis or monitoring of chronic inflammatory airway disease,		
PT	comprises determining the level of the ILM receptor expressed in a		
PT	macrophage.		
XX	Claim 7; Page 72-74; 79pp; English.		
CC	The invention relates to determining an expression level of an ILM		
CC	receptor (macrophage surface receptor), comprises determining the level		
CC	of an ILM receptor expressed in a macrophage. Also included are a method		
CC	of determining whether a substance is an activator or an inhibitor of an		
CC	ILM receptor, involving applying the substance to a test system which		
CC	generates a measurable read-out upon modulation of the ILM receptor or an		
CC	ILM receptor function, a test system for determining whether a substance		
CC	is an activator or an inhibitor of an ILM receptor function,		
CC	characterised in that the receptor is involved in a chronic inflammatory		
CC	airway disease and where the receptor plays a role in mediating		
CC	inflammation comprising: (i) an ILM receptor; (ii) an expression vector		
CC	capable of expressing an ILM receptor in a cell; or (iii) a host cell		
CC	transformed with an expression vector capable of expressing the ILM		
CC	receptor and a substance determined to be an activator or inhibitor of an		
CC	ILM receptor. The methods are useful for the diagnosis or monitoring of a		
CC	chronic inflammatory airway disease, e.g. chronic bronchitis and chronic		
CC	obstructive pulmonary disease (COPD). The substance determined to be an		
CC	activator or inhibitor of an ILM receptor, is useful for treating the		
CC	diseases and for modulating an ILM receptor, in a macrophage. The present		
CC	sequence is an ILM receptor which is differentially expressed and which		
CC	is involved in causing the induction and/or maintenance of the		
CC	hyperactive status of macrophages involved in an inflammatory process		
XX	Sequence 387 AA;		
SQ	Query Match	95.6%; Score 1990; DB 5; Length 387;	
	Best Local Similarity	95.9%; Pred. No. 1.7e-197;	
	Matches 371; Conservative	6; Mismatches 10; Indels 0; Gaps 0;	

PS Disclosure; Fig 1; 523pp; English.

XX The present invention describes antigenic peptides (I) comprising: (a)  
CC any one of 1601 sequences (see ABP2019 to ABP83619) of 12-24 amino  
CC acids. Also described: (1) an assay for the detection of a particular G  
CC protein-coupled receptor (GPCR) or a candidate polypeptide in a sample;  
CC and (2) an isolated antibody having high specificity and high affinity or  
CC avidity for a particular GPCR. (I) can be used as GPCR modulators and in  
CC gene therapy. The antigenic peptides for GPCRs are useful in detecting an  
CC antibody against a particular GPCR, and in the production of specific  
CC antibodies. The peptides and antibodies are also useful for detecting the  
CC presence or absence of corresponding GPCRs. The antigenic peptides for  
CC GPCRs and antibodies are useful for diagnosing and designing drugs for  
CC treating immune-related diseases, growth-related diseases, cell  
CC regeneration-related disease, immunological-related cell proliferative  
CC diseases, or autoimmune diseases, e.g. AIDS, Alzheimer's disease,  
CC atherosclerosis, bacterial, fungal, protozoan or viral infections,  
CC osteoarthritis, osteoporosis, cancer, cardiomyopathy, chronic and acute  
CC inflammation, allergies, Crohn's disease, diabetes, graft versus host  
CC disease, Parkinson's disease, multiple sclerosis, pain, psoriasis, memory  
CC loss, epilepsy, asthma, tuberculosis, obesity, nausea, hypertension, or  
CC anxiety, depression, schizophrenia, dementia, mental retardation, memory  
CC hypotension, renal disorders, rheumatoid arthritis, trauma, ulcers, or  
CC any other disorder in which GPCRs are involved. The antibodies may be  
CC used in immunoassays and immunodiagnosis. AB242523 to AB242869 encode  
CC GPCR proteins given in ABP1675 to ABP2018, which are used in the  
CC exemplification of the present invention

XX SQ Sequence 387 AA;

Query Match 95.6%; Score 1990; DB 6; Length 387;

Best Local Similarity 95.9%; Pred. No. 1.7e-197;

Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

QY 1 MNRHLDQDFLEIDKKNCCVFRDDFIVKVLPPVGLGFIIFGLGNGLALWIFCFHLKSWK 60

DB 1 MNRHLDQDFLEIDKKNCCVFRDDFIVKVLPPVGLGFIIFGLGNGLALWIFCFHLKSWK 60

QY 61 SSRIFLNLAVADFLIIICLPFLMDNVYVRWDKFGDIPCRMLFMLAMNRQSGIIFLTV 120

DB 61 SSRIFLNLAVADFLIIICLPFLMDNVYVRWDKFGDIPCRMLFMLAMNRQSGIIFLTV 120

QY 121 VAVDRYFRVPHHALNKISNRTAAIISCLLWGITIGTLVHLKXKMPIONGGANLCSSF 180

DB 121 VAVDRYFRVPHHALNKISNRTAAIISCLLWGITIGTLVHLKXKLLQNGPANVCISF 180

QY 181 SICTFQWHEAMFLEFFLPLGILFCSARIISLQRQMDRHAQIKRAITFIMVVAIVF 240

DB 181 SICTFQWHEAMFLEFFLPLGILFCSARIISLQRQMDRHAQIKRAITFIMVVAIVF 240

QY 241 VICFLPSVVVRIRIFWLLHTSGTQNCVRSVDLAFFITLSFTYMNMLDPVVVYFSSPS 300

DB 241 VICFLPSVVVRIRIFWLLHTSGTQNCVRSVDLAFFITLSFTYMNMLDPVVVYFSSPS 300

QY 301 FPNFFSTLNRCLQRKMTGPDNNRSTSVELTGDPNKTRGAPALMANSGEPSVYIGP 360

DB 301 FPNFFSTLNRCLQRKMTGPDNNRSTSVELTGDPNKTRGAPALMANSGEPSVYIGP 360

QY 361 TSNNHKKGHCHQEPASLEKQLGCCIE 387

DB 361 TSNNHKKGHCHQEPASLEKQLGCCIE 387

RESULT 14

ID ADC22627

XX ADC22627 standard; protein; 387 AA.

AC ADC22627;

XX 18-DEC-2003 (first entry)

XX Human G protein-coupled receptor (GPCR) polypeptide #29.

\_XX

KW Human; G protein-coupled receptor; GPCR; transmembrane-6 region; TM6;  
KW intracellular-3 region; IC3; receptor.

XX Homo sapiens.

XX US6555339-B1.

XX 29-APR-2003.

XX 13-OCT-1998; 98US-00170496.

XX 14-APR-1997; 97US-00839449.

XX 14-APR-1998; 98US-00060188.

XX 26-JUN-1998; 98US-0090783P.

XX 07-AUG-1998; 98US-0095677P.

XX (AREN-) ARENA PHARM INC.

XX Liaw CW, Behan DP, Chalmers DT;

XX WPI; 2003-742861/70.

XX N-PSDB; ADC22626.

XX Creating a constitutively active version of an endogenous human G protein  
XX coupled receptor (GPCR) comprises substituting a specific amino acid in  
XX the transmembrane-6 region with a different amino acid, and testing for  
XX constitutive activity.

XX Example 1; SEQ ID NO 108; 221pp; English.

XX The invention relates to a method for treating a non-endogenous,  
XX constitutively active version of an endogenous human G protein-coupled  
XX receptor (GPCR) that has a transmembrane-6 (TM6) region and an  
XX intracellular-3 (IC3) region, by substituting a specific amino acid in  
XX the TM6 region with a different amino acid, and testing for constitutive  
XX activity. The method is useful for creating a constitutively active  
XX version of an endogenous human GPCR that comprises a transmembrane 6  
XX region and an intracellular loop 3 region. The altered human GPCR  
XX polypeptides are useful for screening test compounds for identification  
XX of inverse agonists or partial agonists of GPCR polypeptides, which may  
XX have therapeutic uses. The altered GPCRs may also be used in vivo or in  
XX vitro in biological research. A nucleic acid encoding the altered GPCR  
XX may be used to create a transgenic animal expressing the altered GPCR.  
XX The method allows screening for compounds that modulate the activity of a  
XX human G protein-coupled receptor without the need for provision of a  
XX ligand for the receptor. This is particularly useful in allowing  
XX screening of compounds against orphan receptors for which no ligand is  
XX currently known. This sequence represents a human GPCR polypeptide of the  
XX invention.

XX Sequence 387 AA;

Query Match 95.6%; Score 1990; DB 7; Length 387;

Best Local Similarity 95.9%; Pred. No. 1.7e-197;

Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

QY 1 MNRHLDQDFLEIDKKNCCVFRDDFIVKVLPPVGLGFIIFGLGNGLALWIFCFHLKSWK 60

DB 1 MNRHLDQDFLEIDKKNCCVFRDDFIVKVLPPVGLGFIIFGLGNGLALWIFCFHLKSWK 60

QY 61 SSRIFLNLAVADFLIIICLPFLMDNVYVRWDKFGDIPCRMLFMLAMNRQSGIIFLTV 120

DB 61 SSRIFLNLAVADFLIIICLPFLMDNVYVRWDKFGDIPCRMLFMLAMNRQSGIIFLTV 120

QY 121 VAVDRYFRVPHHALNKISNRTAAIISCLLWGITIGTLVHLKXKMPIONGGANLCSSF 180

DB 121 VAVDRYFRVPHHALNKISNRTAAIISCLLWGITIGTLVHLKXKLLQNGPANVCISF 180

QY 181 SICTFQWHEAMFLEFFLPLGILFCSARIISLQRQMDRHAQIKRAITFIMVVAIVF 240

DB 181 SICTFQWHEAMFLEFFLPLGILFCSARIISLQRQMDRHAQIKRAITFIMVVAIVF 240

QY 241 VICFLPSVVVRIRIFWLLHTSGTQNCVRSVDLAFFITLSFTYMNMLDPVVVYFSSPS 300

Db 241 VICFLPSVVVRIIFWLLHTSGTQNCVYRSVDLAFFITLSFTYNSMLDPPVVFSSPS 300  
 Qy 301 FPNFFSTLINCLQKMTGEPDNNRSTSVELTGPDKTRGAPEALMANSGEPMSPSYLGP 360  
 Db 301 FPNFFSTLINCLQKMTGEPDNNRSTSVELTGPDKTRGAPEALMANSGEPMSPSYLGP 360  
 Qy 361 TSNNHKKGGHCHQBPASLEKOLGCCIE 387  
 Db 361 TSNNHKKGGHCHQBPASLEKOLGCCIE 387

RESULT 15  
 ADH14100  
 ID ADH14100 standard; protein; 387 AA.  
 AC ADH14100;  
 XX  
 XX  
 DT 11-MAR-2004 (first entry)  
 XX Human HM74.  
 XX  
 XX human; non-endogenous; G protein-coupled receptor; GPCR; receptor.  
 KW Homo sapiens.  
 XX  
 OS  
 XX  
 PN US2003105292-A1.  
 XX  
 PD 05-JUN-2003.  
 XX  
 PF 20-SEP-2002; 2002US-00251385.  
 XX  
 PR 26-JUN-1998; 98US-0090783P.  
 PR 07-AUG-1998; 98US-0095677P.  
 PR 13-OCT-1998; 98US-00170496.  
 XX  
 XX (LIAW/) LIAW C W.  
 PA (BEHA/) BEHAN D P.  
 PA (CHAL/) CHALMERS D T.  
 XX  
 XX Liaw CW, Behan DP, Chalmers DT;  
 XX  
 XX WPI; 2003-801247/75.  
 DR N-PSDB; ADH14099.  
 XX

New constitutively active, non-endogenous version of an endogenous human G protein-coupled receptor for the identification of therapeutic compounds, such as agonists.

Example 1; SEQ ID NO 108; 227pp; English.

The invention relates to a constitutively active, non-endogenous version of an endogenous human G protein-coupled receptor (GPCR). The GPCR is used for screening therapeutic compounds as inverse agonists, agonists or partial agonists. The GPCR can be also be used to elucidate and understand the roles of GPCRs in normal and diseased humans. The GPCR need not be purified and isolated to be used to screen for therapeutic compounds. The utility of the GPCR as a research tool is enhanced because the role of a particular receptor can be understood before the endogenous ligand is identified. The present sequence is used in the exemplification of the present invention.

XX Sequence 387 AA;

Query Match 95.6%; Score 1990; DB 7; Length 387;  
 Best Local Similarity 95.9%; Pred. No. 1.7e-197;  
 Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

Qy 1 MNRHLDQHFLEIDKNCVFRDDFIVKVLPPVLGLBFIQGLGNGLMIFCFHLKSWK 60  
 Db 1 MNRHLDQHFLEIDKNCVFRDDFIVKVLPPVLGLBFIQGLGNGLMIFCFHLKSWK 60  
 Qy 61 SSRIFLENLAVADFLLIICLPFYMDYVRRSDWNFGDIPCKRLVLFMFAMNRQGSIIFLT 120

Db 61 SSRIFLENLAVADFLLIICLPFYMDYVRRSDWNFGDIPCKRLVLFMFAMNRQGSIIFLT 120  
 Qy 121 VAVDRYFRVPHPHALNKISNRATAAISCLLWGITIGLTVHLLKKKMPIONGGANLCSF 180  
 Db 121 VAVDRYFRVPHPHALNKISNRATAAISCLLWGITIGLTVHLLKKKLLIQNGPANVCISF 180  
 Qy 181 SICTHFWHEAMFLLEFFLPLGIIILFCSARIINSLRQRMDRHAKIKRAITFIWVAIVF 240  
 Db 181 SICTHFWHEAMFLLEFFLPLGIIILFCSARIINSLRQRMDRHAKIKRAITFIWVAIVF 240  
 Qy 241 VICFLPSVVVRIIFWLLHTSGTQNCVYRSVDLAFFITLSFTYNSMLDPPVVFSSPS 300  
 Db 241 VICFLPSVVVRIIFWLLHTSGTQNCVYRSVDLAFFITLSFTYNSMLDPPVVFSSPS 300  
 Qy 301 FPNFFSTLINCLQKMTGEPDNNRSTSVELTGPDKTRGAPEALMANSGEPMSPSYLGP 360  
 Db 301 FPNFFSTLINCLQKMTGEPDNNRSTSVELTGPDKTRGAPEALMANSGEPMSPSYLGP 360  
 Qy 361 TSNNHKKGGHCHQBPASLEKOLGCCIE 387  
 Db 361 TSNNHKKGGHCHQBPASLEKOLGCCIE 387

Search completed: October 20, 2005, 06:03:07  
 Job time : 72 secs



This Page Blank (uspto)

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 20, 2005, 06:02:31 ; Search time 4754 Seconds  
(without alignments)  
33.986 Million cell updates/sec

Title: US-10-800-249-2

Perfect score: 2081

Sequence: 1 MNRHLLQDHFLEIDKKNCCV.....KGHCQBPALEKQLGCCIE 387

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1862951 seqs, 417491010 residues

Total number of hits satisfying chosen parameters: 1862951

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:\*

- 1: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep.\*
- 2: /cgn2\_6/ptodata/1/pubpaa/PCT\_NEW\_PUB.pep.\*
- 3: /cgn2\_6/ptodata/1/pubpaa/US06\_NEW\_PUB.pep.\*
- 4: /cgn2\_6/ptodata/1/pubpaa/US06\_PUBCOMB.pep.\*
- 5: /cgn2\_6/ptodata/1/pubpaa/US07\_NEW\_PUB.pep.\*
- 6: /cgn2\_6/ptodata/1/pubpaa/PCTUS\_PUBCOMB.pep.\*
- 7: /cgn2\_6/ptodata/1/pubpaa/US08\_NEW\_PUB.pep.\*
- 8: /cgn2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pep.\*
- 9: /cgn2\_6/ptodata/1/pubpaa/US09A\_PUBCOMB.pep.\*
- 10: /cgn2\_6/ptodata/1/pubpaa/US09B\_PUBCOMB.pep.\*
- 11: /cgn2\_6/ptodata/1/pubpaa/US09C\_PUBCOMB.pep.\*
- 12: /cgn2\_6/ptodata/1/pubpaa/US09\_NEW\_PUB.pep.\*
- 13: /cgn2\_6/ptodata/1/pubpaa/US10A\_PUBCOMB.pep.\*
- 14: /cgn2\_6/ptodata/1/pubpaa/US10B\_PUBCOMB.pep.\*
- 15: /cgn2\_6/ptodata/1/pubpaa/US10C\_PUBCOMB.pep.\*
- 16: /cgn2\_6/ptodata/1/pubpaa/US10D\_PUBCOMB.pep.\*
- 17: /cgn2\_6/ptodata/1/pubpaa/US10E\_PUBCOMB.pep.\*
- 18: /cgn2\_6/ptodata/1/pubpaa/US10\_NEW\_PUB.pep.\*
- 19: /cgn2\_6/ptodata/1/pubpaa/US11A\_PUBCOMB.pep.\*
- 20: /cgn2\_6/ptodata/1/pubpaa/US11\_NEW\_PUB.pep.\*
- 21: /cgn2\_6/ptodata/1/pubpaa/US60\_NEW\_PUB.pep.\*
- 22: /cgn2\_6/ptodata/1/pubpaa/US60\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	2081	100.0	387	18	US-10-800-249-2
2	1996	95.9	387	10	US-09-930-334-2
3	1996	95.9	387	15	US-10-619-141-2
4	1995	95.9	387	15	US-10-295-027-224
5	1995	95.9	387	15	US-10-188-832-108
6	1995	95.9	625	17	US-10-505-486-86
7	1990	95.6	387	9	US-09-944-807-21
8	1990	95.6	387	14	US-10-092-135-8
9	1990	95.6	387	14	US-10-251-385-108
10	1990	95.6	387	14	US-10-240-842-4
11	1990	95.6	387	14	US-10-225-567A-281

12	1990	95.6	387	14	US-10-296-223-4	Sequence 4, Appli
13	1990	95.6	387	14	US-10-348-083-3	Sequence 3, Appli
14	1990	95.6	387	14	US-10-044-643-43	Sequence 43, Appli
15	1990	95.6	387	15	US-10-295-027-228	Sequence 228, App
16	1990	95.6	387	16	US-10-314-048A-135	Sequence 135, App
17	1990	95.6	387	16	US-10-789-241-6	Sequence 6, Appli
18	1990	95.6	387	16	US-10-874-015-21	Sequence 21, Appli
19	1990	95.6	387	17	US-10-897-815-135	Sequence 135, App
20	1990	95.6	387	18	US-10-930-662-135	Sequence 135, App
21	1990	95.6	387	18	US-10-800-249-3	Sequence 3, Appli
22	1988	95.5	387	14	US-10-251-385-222	Sequence 222, App
23	1935	93.0	363	14	US-10-321-807-36	Sequence 36, Appli
24	1935	93.0	363	15	US-10-295-027-226	Sequence 226, App
25	1935	93.0	363	15	US-10-292-798-668	Sequence 668, App
26	1935	93.0	363	16	US-10-321-807-36	Sequence 36, Appli
27	1935	93.0	363	16	US-10-314-048A-36	Sequence 36, Appli
28	1935	93.0	363	17	US-10-897-815-36	Sequence 36, Appli
29	1935	93.0	363	18	US-10-930-662-36	Sequence 36, Appli
30	1935	93.0	363	18	US-10-800-249-4	Sequence 4, Appli
31	1930	92.7	363	10	US-09-930-334-16	Sequence 16, Appli
32	1930	92.7	363	15	US-10-619-141-16	Sequence 16, Appli
33	1921	92.3	363	16	US-10-314-048A-159	Sequence 159, App
34	1921	92.3	363	17	US-10-897-815-159	Sequence 159, App
35	1921	92.3	363	18	US-10-930-662-159	Sequence 159, App
36	1871	89.9	363	16	US-10-484-788-12	Sequence 12, Appli
37	1864	89.6	392	14	US-10-017-161-808	Sequence 808, App
38	1858	89.3	364	14	US-10-017-161-766	Sequence 766, App
39	1717	82.5	339	14	US-10-188-149A-4	Sequence 4, Appli
40	1670	80.2	363	16	US-10-484-788-14	Sequence 14, Appli
41	1591	76.5	360	16	US-10-484-788-10	Sequence 10, Appli
42	1577	75.8	360	14	US-10-044-643-44	Sequence 44, Appli
43	1577	75.8	360	16	US-10-314-048A-137	Sequence 137, App
44	1577	75.8	360	16	US-10-484-788-8	Sequence 8, Appli
45	1577	75.8	360	17	US-10-897-815-137	Sequence 137, App

ALIGNMENTS

RESULT 1

US-10-800-249-2  
; Sequence 2, Application US/10800249  
; Publication No. US20050227238A1  
; GENERAL INFORMATION:  
; APPLICANT: Bristol-Myers Squibb Company  
; TITLE OF INVENTION: POLYNUCLEOTIDE ENCODING A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR  
; TITLE OF INVENTION: VARIANT OF HM74, HGPRBMV74  
; FILE REFERENCE: D0323 NP  
; CURRENT APPLICATION NUMBER: US/10/800,249  
; PRIOR FILING DATE: 2004-03-12  
; PRIOR APPLICATION NUMBER: U.S. 60/454,942  
; PRIOR FILING DATE: 2003-03-14  
; NUMBER OF SEQ ID NOS: 58  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 2  
; LENGTH: 387  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-800-249-2

Query Match	100.0%;	Score	2081;	DB	18;	Length	387;
Best Local Similarity	100.0%;	Pred. No.	5e-179;				
Matches	387;	Conservative	0;	Mismatches	0;	Indels	0;
Gaps	0;						
Qy	1	MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVVLGLEFIFGLLGNGLALMIFCFLHLSWK	60				
Db	1	MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVVLGLEFIFGLLGNGLALMIFCFLHLSWK	60				
Qy	61	SSRIFLENLAVADFLIICLPFLMDNVYVRWDKFGDIPCLRMLFMLAMNRQGSIIFLT	120				
Db	61	SSRIFLENLAVADFLIICLPFLMDNVYVRWDKFGDIPCLRMLFMLAMNRQGSIIFLT	120				
Qy	121	VAVDRYPRVPHHALNKISNRTAALISCLLWGTITGLTVHLLKKKWPIONGGANLCSF	180				

```
Db 121 VAVDRYFRVPHALNKNISNRATAIISCLLWGITGLTVHLLKKXQPIQNGANLCSSF 180
QY 181 SICHTFQWHEAMFLLFFPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
Db 181 SICHTFQWHEAMFLLFFPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
QY 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMSMLDPVVYYFSSPS 300
Db 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMSMLDPVVYYFSSPS 300
QY 301 FPNFFSTLINRCLQRKWTGEPDNNRSTSVELTGDPNKTRGAPALMANSGEPMSPSYLGP 360
Db 301 FPNFFSTLINRCLQRKWTGEPDNNRSTSVELTGDPNKTRGAPALMANSGEPMSPSYLGP 360
QY 361 TSNNHSHKKGHCHEPASPASLEKQLGCCIE 387
Db 361 TSNNHSHKKGHCHEPASPASLEKQLGCCIE 387

RESULT 2
US-09-930-334-2
; Sequence 2, Application US/09930334
; Publication No. US20030078218A1
; GENERAL INFORMATION:
; APPLICANT: Gabor Jarai and Shida Yousefi
; TITLE OF INVENTION: Inflammation related G-protein coupled receptor
; FILE REFERENCE: 4-31553A/HO 33
; CURRENT APPLICATION NUMBER: US/09/930,334
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 2
; LENGTH: 387
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-930-334-2

Query Match 95.9%; Score 1996; DB 10; Length 387;
Best Local Similarity 96.1%; Pred. No. 2.3e-171;
Matches 372; Conservative 6; Mismatches 9; Indels 0; Gaps 0;

QY 1 MNRHHLQDHLEIDKKNCCVFRDDFTIVKVLPPVLGLEFTFGLLGNGLALWIFCFHLKSWK 60
Db 1 MNRHHLQDHLEIDKKNCCVFRDDFTIAKVLPPVLGLEFTFGLLGNGLALWIFCFHLKSWK 60
QY 61 SSRIFLNLAVADFLIILCLPFLMDNYVRRWDKFGDIPCRMLFMLAMNRQGSIIFLT 120
Db 61 SSRIFLNLAVADFLIILCLPFLMDNYVRRWDKFGDIPCRMLFMLAMNRQGSIIFLT 120
QY 121 VAVDRYFRVPHALNKNISNRATAIISCLLWGITGLTVHLLKKXQPIQNGANLCSSF 180
Db 121 VAVDRYFRVPHALNKNISNRATAIISCLLWGITGLTVHLLKKXQPIQNGANLCSSF 180
QY 181 SICHTFQWHEAMFLLFFPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
Db 181 SICHTFQWHEAMFLLFFPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
QY 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMSMLDPVVYYFSSPS 300
Db 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMSMLDPVVYYFSSPS 300
QY 301 FPNFFSTLINRCLQRKWTGEPDNNRSTSVELTGDPNKTRGAPALMANSGEPMSPSYLGP 360
Db 301 FPNFFSTLINRCLQRKWTGEPDNNRSTSVELTGDPNKTRGAPALMANSGEPMSPSYLGP 360
QY 361 TSNNHSHKKGHCHEPASPASLEKQLGCCIE 387
Db 361 TSNNHSHKKGHCHEPASPASLEKQLGCCIE 387

US-10-619-141-2
```

```
Query Match 95.9%; Score 1996; DB 10; Length 387;
Best Local Similarity 96.1%; Pred. No. 2.3e-171;
Matches 372; Conservative 6; Mismatches 9; Indels 0; Gaps 0;

QY 1 MNRHHLQDHLEIDKKNCCVFRDDFTIVKVLPPVLGLEFTFGLLGNGLALWIFCFHLKSWK 60
Db 1 MNRHHLQDHLEIDKKNCCVFRDDFTIAKVLPPVLGLEFTFGLLGNGLALWIFCFHLKSWK 60
QY 61 SSRIFLNLAVADFLIILCLPFLMDNYVRRWDKFGDIPCRMLFMLAMNRQGSIIFLT 120
Db 61 SSRIFLNLAVADFLIILCLPFLMDNYVRRWDKFGDIPCRMLFMLAMNRQGSIIFLT 120
QY 121 VAVDRYFRVPHALNKNISNRATAIISCLLWGITGLTVHLLKKXQPIQNGANLCSSF 180
Db 121 VAVDRYFRVPHALNKNISNRATAIISCLLWGITGLTVHLLKKXQPIQNGANLCSSF 180
QY 181 SICHTFQWHEAMFLLFFPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
Db 181 SICHTFQWHEAMFLLFFPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
QY 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMSMLDPVVYYFSSPS 300
Db 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMSMLDPVVYYFSSPS 300
QY 301 FPNFFSTLINRCLQRKWTGEPDNNRSTSVELTGDPNKTRGAPALMANSGEPMSPSYLGP 360
Db 301 FPNFFSTLINRCLQRKWTGEPDNNRSTSVELTGDPNKTRGAPALMANSGEPMSPSYLGP 360
QY 361 TSNNHSHKKGHCHEPASPASLEKQLGCCIE 387
Db 361 TSNNHSHKKGHCHEPASPASLEKQLGCCIE 387

US-10-619-141-2
```

RESULT 3

US-10-619-141-2

```
; Sequence 2, Application US/10619141
; Publication No. US20040038895A1
; GENERAL INFORMATION:
; APPLICANT: Gabor Jarai and Shida Yousefi
; TITLE OF INVENTION: Inflammation related G-protein coupled receptor
; FILE REFERENCE: 4-31553A/HO 33
; CURRENT APPLICATION NUMBER: US/10/619,141
; CURRENT FILING DATE: 2003-07-14
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 2
; LENGTH: 387
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-619-141-2

Query Match 95.9%; Score 1996; DB 15; Length 387;
Best Local Similarity 96.1%; Pred. No. 2.3e-171;
Matches 372; Conservative 6; Mismatches 9; Indels 0; Gaps 0;

QY 1 MNRHHLQDHLEIDKKNCCVFRDDFTIVKVLPPVLGLEFTFGLLGNGLALWIFCFHLKSWK 60
Db 1 MNRHHLQDHLEIDKKNCCVFRDDFTIAKVLPPVLGLEFTFGLLGNGLALWIFCFHLKSWK 60
QY 61 SSRIFLNLAVADFLIILCLPFLMDNYVRRWDKFGDIPCRMLFMLAMNRQGSIIFLT 120
Db 61 SSRIFLNLAVADFLIILCLPFLMDNYVRRWDKFGDIPCRMLFMLAMNRQGSIIFLT 120
QY 121 VAVDRYFRVPHALNKNISNRATAIISCLLWGITGLTVHLLKKXQPIQNGANLCSSF 180
Db 121 VAVDRYFRVPHALNKNISNRATAIISCLLWGITGLTVHLLKKXQPIQNGANLCSSF 180
QY 181 SICHTFQWHEAMFLLFFPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
Db 181 SICHTFQWHEAMFLLFFPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
QY 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMSMLDPVVYYFSSPS 300
Db 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMSMLDPVVYYFSSPS 300
QY 301 FPNFFSTLINRCLQRKWTGEPDNNRSTSVELTGDPNKTRGAPALMANSGEPMSPSYLGP 360
Db 301 FPNFFSTLINRCLQRKWTGEPDNNRSTSVELTGDPNKTRGAPALMANSGEPMSPSYLGP 360
QY 361 TSNNHSHKKGHCHEPASPASLEKQLGCCIE 387
Db 361 TSNNHSHKKGHCHEPASPASLEKQLGCCIE 387

RESULT 4
US-10-295-027-224
; Sequence 224, Application US/10295027
; Publication No. US20030232350A1
; GENERAL INFORMATION:
; APPLICANT: Afar, Daniel
; APPLICANT: Aziz, Natasha
; APPLICANT: Ginsberg, Wendy M.
; APPLICANT: Gish, Kurt C.
; APPLICANT: Glynn, Richard
; APPLICANT: Hevezi, Peter A.
; APPLICANT: Mack, David H.
; APPLICANT: Murray, Richard
; APPLICANT: Watson, Susan R.
; APPLICANT: Bos Biotechnology, Inc.
; TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and
; FILE REFERENCE: 018501-012500US
; CURRENT APPLICATION NUMBER: US/10/295,027
; CURRENT FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: US 09/663,733
; PRIOR FILING DATE: 2000-09-15
; PRIOR APPLICATION NUMBER: US 60/350,666
; PRIOR FILING DATE: 2001-11-13
```

```
; PRIOR APPLICATION NUMBER: US 60/335,394
; PRIOR FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: US 60/332,464
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: US 60/334,393
; PRIOR FILING DATE: 2001-11-29
; PRIOR APPLICATION NUMBER: US 60/340,376
; PRIOR FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: US 60/347,211
; PRIOR FILING DATE: 2002-01-08
; PRIOR APPLICATION NUMBER: US 60/347,349
; PRIOR FILING DATE: 2002-01-10
; PRIOR APPLICATION NUMBER: US 60/355,250
; PRIOR FILING DATE: 2002-02-08
; PRIOR APPLICATION NUMBER: US 60/356,714
; PRIOR FILING DATE: 2002-02-13
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1386
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 224
; LENGTH: 387
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-295-027-224

Query Match      95.9%; Score 1995; DB 15; Length 387;
Best Local Similarity 96.1%; Pred. No. 2.8e-171;
Matches 372; Conservative 6; Mismatches 9; Indels 0; Gaps 0;

Qy 1 MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVGLGFIIFGLLGNGLALMIFCFHLKSWK 60
Db 1 MNRHLLQDHFLEIDKKNCCVFRDDFIAKVLPPVGLGFIIFGLLGNGLALMIFCFHLKSWK 60

Qy 61 SSRIFLNLAVADFLLIICLPFLMDNVYRWDWKFQDIPCLRLMFLMAMNRQGSIIIFLTV 120
Db 61 SSRIFLNLAVADFLLIICLPFLMDNVYRWDWKFQDIPCLRLMFLMAMNRQGSIIIFLTV 120

Qy 121 VADRYFRVPHPHALNKISNRTAAIISCLLWGITIGLTVHLLKKKPIONGGANLCSF 180
Db 121 VADRYFRVPHPHALNKISNRTAAIISCLLWGITIGLTVHLLKKKPIONGGANLCSF 180

Qy 181 SICHTFOWHEAMFLEFLPLGIILFCSARIISLQRODRHAKIKRAITFINVVAIVF 240
Db 181 SICHTFOWHEAMFLEFLPLGIILFCSARIISLQRODRHAKIKRAITFINVVAIVF 240

Qy 241 VICFLPSVVVIRIFWLLHSTGTONCEVYRSDVLAFFITLSFTYNSMLDPVVYFSSPS 300
Db 241 VICFLPSVVVIRIFWLLHSTGTONCEVYRSDVLAFFITLSFTYNSMLDPVVYFSSPS 300

Qy 301 FPNFFSTLINRCLQKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSCEPWPSPSYLGP 360
Db 301 FPNFFSTLINRCLQKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSCEPWPSPSYLGP 360

Qy 361 TSNHSHKKGCHQBPASLEKLGCCIE 387
Db 361 TSNHSHKKGCHQBPASLEKLGCCIE 387

RESULT 5
US-10-188-832-108
; Sequence 108, Application US/10188832
; Publication No. US20040076955A1
; GENERAL INFORMATION:
; APPLICANT: MacK, David H.
; APPLICANT: Aziz, Natasha
; APPLICANT: Eos Biotechnology, Inc.
; TITLE OF INVENTION: Methods of Diagnosis of Bladder Cancer, Compositions
; TITLE OF INVENTION: and Methods of Screening for Modulators of Bladder
; TITLE OF INVENTION: Cancer
; FILE REFERENCE: 018501-002330US
; CURRENT APPLICATION NUMBER: US/10/188,832
; PRIOR FILING DATE: 2002-11-22
; PRIOR APPLICATION NUMBER: US 60/302,814
```

```
; PRIOR FILING DATE: 2001-07-03
; PRIOR APPLICATION NUMBER: US 60/310,099
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: US 60/343,705
; PRIOR FILING DATE: 2001-11-08
; PRIOR APPLICATION NUMBER: US 60/350,666
; PRIOR FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: US 60/372,246
; PRIOR FILING DATE: 2002-04-12
; NUMBER OF SEQ ID NOS: 207
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 108
; LENGTH: 387
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-188-832-108

Query Match      95.9%; Score 1995; DB 15; Length 387;
Best Local Similarity 96.1%; Pred. No. 2.8e-171;
Matches 372; Conservative 6; Mismatches 9; Indels 0; Gaps 0;

Qy 1 MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVGLGFIIFGLLGNGLALMIFCFHLKSWK 60
Db 1 MNRHLLQDHFLEIDKKNCCVFRDDFIAKVLPPVGLGFIIFGLLGNGLALMIFCFHLKSWK 60

Qy 61 SSRIFLNLAVADFLLIICLPFLMDNVYRWDWKFQDIPCLRLMFLMAMNRQGSIIIFLTV 120
Db 61 SSRIFLNLAVADFLLIICLPFLMDNVYRWDWKFQDIPCLRLMFLMAMNRQGSIIIFLTV 120

Qy 121 VADRYFRVPHPHALNKISNRTAAIISCLLWGITIGLTVHLLKKKPIONGGANLCSF 180
Db 121 VADRYFRVPHPHALNKISNRTAAIISCLLWGITIGLTVHLLKKKPIONGGANLCSF 180

Qy 181 SICHTFOWHEAMFLEFLPLGIILFCSARIISLQRODRHAKIKRAITFINVVAIVF 240
Db 181 SICHTFOWHEAMFLEFLPLGIILFCSARIISLQRODRHAKIKRAITFINVVAIVF 240

Qy 241 VICFLPSVVVIRIFWLLHSTGTONCEVYRSDVLAFFITLSFTYNSMLDPVVYFSSPS 300
Db 241 VICFLPSVVVIRIFWLLHSTGTONCEVYRSDVLAFFITLSFTYNSMLDPVVYFSSPS 300

Qy 301 FPNFFSTLINRCLQKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSCEPWPSPSYLGP 360
Db 301 FPNFFSTLINRCLQKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSCEPWPSPSYLGP 360

Qy 361 TSNHSHKKGCHQBPASLEKLGCCIE 387
Db 361 TSNHSHKKGCHQBPASLEKLGCCIE 387

RESULT 6
US-10-505-486-86
; Sequence 86, Application US/10505486
; Publication No. US20050118639A1
; GENERAL INFORMATION:
; APPLICANT: Takeda Chemical Industries, Ltd.
; TITLE OF INVENTION: Determination of a ligand
; FILE REFERENCE: P03-0006PCT
; CURRENT APPLICATION NUMBER: US/10/505,486
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: JP 2002-45728
; PRIOR FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: JP 2002-213949
; PRIOR FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: JP 2002-298237
; PRIOR FILING DATE: 2002-10-11
; NUMBER OF SEQ ID NOS: 233
; SEQ ID NO 86
; LENGTH: 625
; TYPE: PRT
; ORGANISM: Human
US-10-505-486-86
```

Query Match 95.9%; Score 1995; DB 17; Length 625;  
Best Local Similarity 96.1%; Pred. No. 5e-171;  
Matches 372; Conservative 6; Mismatches 9; Indels 0; Gaps 0;

QY 1 MNRHLLQDHLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWK 60  
DB 1 MNRHLLQDHLEIDKKNCCVFRDDFIAKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWK 60

QY 61 SSRIFLNLAVADFLLIICLPFLMDNVYVRWDKFGDIPCRLLMFLMANNRQSGSIIFLTV 120  
DB 61 SSRIFLNLAVADFLLIICLPFVNDYVVRSDKRFGDIPCRLLVLFMFAMNRQSGSIIFLTV 120

QY 121 VAVDRYFRVVPHHALNKISNRTAAIISCLLWGITTGLTVHLLKKXMPIONGGANLCSSF 180  
DB 121 VAVDRYFRVVPHHALNKISNRTAAIISCLLWGITVGLTVHLLKKLLIQNGPANVCISF 180

QY 181 SICTHFWHEAMFLLEFFPLGLIILFCSARIIWSLRQRMDRHAKIKRAITFTIMVVAIVF 240  
DB 181 SICTHFWHEAMFLLEFFPLGLIILFCSARIIWSLRQRMDRHAKIKRAITFTIMVVAIVF 240

QY 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMSMLDPVVYYFSSPS 300  
DB 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMSMLDPVVYYFSSPS 300

QY 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360  
DB 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360

QY 361 TSNNHKKKGCHQEPASLEKQLGCCIE 387  
DB 361 TSNNHKKKGCHQEPASLEKQLGCCIE 387

RESULT 7  
US-09-944-807-21  
; Sequence 21, Application US/09944807  
; Patent No. US2002011949A1  
; GENERAL INFORMATION:  
; APPLICANT: Boehringer Ingelheim Pharma KG  
; TITLE OF INVENTION: Method for identifying substances which positively  
; TITLE OF INVENTION: influence inflammatory conditions of chronic  
; TITLE OF INVENTION: inflammatory airway diseases  
; FILE REFERENCE: 082.00n  
; CURRENT APPLICATION NUMBER: US/09/944,807  
; CURRENT FILING DATE: 2001-08-31  
; PRIOR APPLICATION NUMBER: UK 0021484.1  
; PRIOR FILING DATE: 2000-09-01  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 387  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-944-807-21

Query Match 95.6%; Score 1990; DB 9; Length 387;  
Best Local Similarity 95.9%; Pred. No. 8e-171;  
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

QY 1 MNRHLLQDHLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWK 60  
DB 1 MNRHLLQDHLEIDKKNCCVFRDDFIAKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWK 60

QY 61 SSRIFLNLAVADFLLIICLPFLMDNVYVRWDKFGDIPCRLLMFLMANNRQSGSIIFLTV 120  
DB 61 SSRIFLNLAVADFLLIICLPFVNDYVVRSDNWFNFGDIPCRLLVLFMFAMNRQSGSIIFLTV 120

QY 121 VAVDRYFRVVPHHALNKISNRTAAIISCLLWGITTGLTVHLLKKXMPIONGGANLCSSF 180  
DB 121 VAVDRYFRVVPHHALNKISNRTAAIISCLLWGITVGLTVHLLKKLLIQNGPANVCISF 180

QY 181 SICTHFWHEAMFLLEFFPLGLIILFCSARIIWSLRQRMDRHAKIKRAITFTIMVVAIVF 240  
DB 181 SICTHFWHEAMFLLEFFPLGLIILFCSARIIWSLRQRMDRHAKIKRAITFTIMVVAIVF 240

QY 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMSMLDPVVYYFSSPS 300  
DB 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMSMLDPVVYYFSSPS 300

QY 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360  
DB 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360

QY 361 TSNNHKKKGCHQEPASLEKQLGCCIE 387  
DB 361 TSNNHKKKGCHQEPASLEKQLGCCIE 387

Db 181 SICTHFWHEAMFLLEFFPLGLIILFCSARIIWSLRQRMDRHAKIKRAITFTIMVVAIVF 240  
QY 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMSMLDPVVYYFSSPS 300  
Db 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMSMLDPVVYYFSSPS 300  
QY 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360  
Db 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360  
QY 361 TSNNHKKKGCHQEPASLEKQLGCCIE 387  
Db 361 TSNNHKKKGCHQEPASLEKQLGCCIE 387

RESULT 8  
US-10-092-135-8  
; Sequence 8, Application US/10092135  
; Publication No. US20030054374A1  
; GENERAL INFORMATION:  
; APPLICANT: Bristol-Myers Squibb Company  
; TITLE OF INVENTION: POLYNUCLEOTIDE ENCODING A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR,  
; FILE REFERENCE: D0134.NP  
; CURRENT APPLICATION NUMBER: US/10/092,135  
; CURRENT FILING DATE: 2002-03-06  
; PRIOR APPLICATION NUMBER: US 60/273,808  
; PRIOR FILING DATE: 2001-03-07  
; PRIOR APPLICATION NUMBER: US 60/278,983  
; PRIOR FILING DATE: 2001-03-27  
; NUMBER OF SEQ ID NOS: 75  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 8  
; LENGTH: 387  
; TYPE: PRT  
; ORGANISM: HOMO SAPIENS  
US-10-092-135-8

Query Match 95.6%; Score 1990; DB 14; Length 387;  
Best Local Similarity 95.9%; Pred. No. 8e-171;  
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

QY 1 MNRHLLQDHLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWK 60  
DB 1 MNRHLLQDHLEIDKKNCCVFRDDFIAKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWK 60

QY 61 SSRIFLNLAVADFLLIICLPFLMDNVYVRWDKFGDIPCRLLMFLMANNRQSGSIIFLTV 120  
DB 61 SSRIFLNLAVADFLLIICLPFVNDYVVRSDNWFNFGDIPCRLLVLFMFAMNRQSGSIIFLTV 120

QY 121 VAVDRYFRVVPHHALNKISNRTAAIISCLLWGITTGLTVHLLKKXMPIONGGANLCSSF 180  
DB 121 VAVDRYFRVVPHHALNKISNRTAAIISCLLWGITVGLTVHLLKKLLIQNGPANVCISF 180

QY 181 SICTHFWHEAMFLLEFFPLGLIILFCSARIIWSLRQRMDRHAKIKRAITFTIMVVAIVF 240  
DB 181 SICTHFWHEAMFLLEFFPLGLIILFCSARIIWSLRQRMDRHAKIKRAITFTIMVVAIVF 240

QY 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMSMLDPVVYYFSSPS 300  
DB 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMSMLDPVVYYFSSPS 300

QY 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360  
DB 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360

QY 361 TSNNHKKKGCHQEPASLEKQLGCCIE 387  
DB 361 TSNNHKKKGCHQEPASLEKQLGCCIE 387

RESULT 9  
US-10-251-385-108

; Sequence 108, Application US/10251385  
; Publication No. US20030105292A1  
; GENERAL INFORMATION:  
; APPLICANT: Behan, Dominic P.  
; APPLICANT: Chalmers, Derek T.  
; APPLICANT: Liaw, Chen W.  
; TITLE OF INVENTION: No. US20030105292A1-Endogenous, Constitutively Activated Human G  
; TITLE OF INVENTION: Protein-Coupled Receptors  
; FILE REFERENCE: AREN-0040  
; CURRENT APPLICATION NUMBER: US/10/251,385  
; CURRENT FILING DATE: 2002-09-20  
; PRIOR APPLICATION NUMBER: US/09/170,496  
; PRIOR FILING DATE: 1998-10-13  
; NUMBER OF SEQ ID NOS: 294  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 108  
; LENGTH: 387  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-251-385-108

Query Match 95.6%; Score 1990; DB 14; Length 387;  
Best Local Similarity 95.9%; Pred. No. 8e-171;  
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

Qy 1 MNRHLLQDHFLEIDKKNCCVFRDDFIKVLPPVLGLFIFGLLGNGLALWIFCFHLKSWK 60  
Db 1 MNRHLLQDHFLEIDKKNCCVFRDDFIKVLPPVLGLFIFGLLGNGLALWIFCFHLKSWK 60

Qy 61 SSRIFLENLAVADPELLIICLPFLMDNVYRRWDKFGDIPCLRLMFLMLAMNRQGSIIIFLTV 120  
Db 61 SSRIFLENLAVADPELLIICLPFLMDNVYRRWDKFGDIPCLRLMFLMLAMNRQGSIIIFLTV 120

Qy 121 VAVDRYFRVPHPHALNKISNRTAAIISCLLWGTTIGLTVHLLKKKMPIONGGANLCSSF 180  
Db 121 VAVDRYFRVPHPHALNKISNRTAAIISCLLWGTTIGLTVHLLKKKMPIONGGANLCSSF 180

Qy 181 SICTFOWHEAMFLEFFPLGLIFCSARIISLRLQRQMDRHAHAKIKRAITFIMVVAIVF 240  
Db 181 SICTFOWHEAMFLEFFPLGLIFCSARIISLRLQRQMDRHAHAKIKRAITFIMVVAIVF 240

Qy 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSTFTYNSMLDPVVYFSSPS 300  
Db 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSTFTYNSMLDPVVYFSSPS 300

Qy 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360  
Db 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360

Qy 361 TSNNHKKKGCHQBPASLEKOLGCCIE 387  
Db 361 TSNNHKKKGCHQBPASLEKOLGCCIE 387

RESULT 11  
US-10-225-567A-281  
; Sequence 281, Application US/10225567A  
; Publication No. US20030113798A1  
; GENERAL INFORMATION:  
; APPLICANT: LifeSpan Biosciences  
; APPLICANT: Brown, Joseph P.  
; APPLICANT: Burmer, Glenn C.  
; APPLICANT: Roush, Christine L.  
; TITLE OF INVENTION: ANTIGENIC PEPTIDES AND ANTIBODIES FOR G PROTEIN-COUPLED RECEPTORS  
; FILE REFERENCE: 1920-4-4  
; CURRENT APPLICATION NUMBER: US/10/225,567A  
; CURRENT FILING DATE: 2001-12-19  
; PRIOR FILING DATE: 60/257,144  
; NUMBER OF SEQ ID NOS: 2292  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 281  
; LENGTH: 387  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-225-567A-281

Query Match 95.6%; Score 1990; DB 14; Length 387;  
Best Local Similarity 95.9%; Pred. No. 8e-171;  
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

Qy 1 MNRHLLQDHFLEIDKKNCCVFRDDFIKVLPPVLGLFIFGLLGNGLALWIFCFHLKSWK 60  
Db 1 MNRHLLQDHFLEIDKKNCCVFRDDFIKVLPPVLGLFIFGLLGNGLALWIFCFHLKSWK 60

Qy 61 SSRIFLENLAVADPELLIICLPFLMDNVYRRWDKFGDIPCLRLMFLMLAMNRQGSIIIFLTV 120  
Db 61 SSRIFLENLAVADPELLIICLPFLMDNVYRRWDKFGDIPCLRLMFLMLAMNRQGSIIIFLTV 120

Qy 121 VAVDRYFRVPHPHALNKISNRTAAIISCLLWGTTIGLTVHLLKKKMPIONGGANLCSSF 180  
Db 121 VAVDRYFRVPHPHALNKISNRTAAIISCLLWGTTIGLTVHLLKKKMPIONGGANLCSSF 180

Qy 181 SICTFOWHEAMFLEFFPLGLIFCSARIISLRLQRQMDRHAHAKIKRAITFIMVVAIVF 240  
Db 181 SICTFOWHEAMFLEFFPLGLIFCSARIISLRLQRQMDRHAHAKIKRAITFIMVVAIVF 240

Qy 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSTFTYNSMLDPVVYFSSPS 300  
Db 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSTFTYNSMLDPVVYFSSPS 300

Qy 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360  
Db 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360

Qy 361 TSNNHKKKGCHQBPASLEKOLGCCIE 387  
Db 361 TSNNHKKKGCHQBPASLEKOLGCCIE 387

RESULT 10  
US-10-240-842-4  
; Sequence 4, Application US/10240842  
; Publication No. US20030109673A1  
; GENERAL INFORMATION:  
; APPLICANT: Xiao, Yonghong  
; TITLE OF INVENTION: REGULATION OF HUMAN HM74-LIKE G PROTEIN-COUPLED RECEPTOR  
; FILE REFERENCE: 4974.00883  
; CURRENT APPLICATION NUMBER: US/10/240,842  
; CURRENT FILING DATE: 2002-10-04  
; PRIOR APPLICATION NUMBER: 60/194,701  
; PRIOR FILING DATE: 2000-04-05  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 4  
; LENGTH: 387  
; TYPE: PRT  
; ORGANISM: Homo sapiens

US-10-240-842-4  
Query Match 95.6%; Score 1990; DB 14; Length 387;  
Best Local Similarity 95.9%; Pred. No. 8e-171;  
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

Qy 1 MNRHLLQDHFLEIDKKNCCVFRDDFIKVLPPVLGLFIFGLLGNGLALWIFCFHLKSWK 60  
Db 1 MNRHLLQDHFLEIDKKNCCVFRDDFIKVLPPVLGLFIFGLLGNGLALWIFCFHLKSWK 60

Qy 61 SSRIFLENLAVADPELLIICLPFLMDNVYRRWDKFGDIPCLRLMFLMLAMNRQGSIIIFLTV 120  
Db 61 SSRIFLENLAVADPELLIICLPFLMDNVYRRWDKFGDIPCLRLMFLMLAMNRQGSIIIFLTV 120

Qy 121 VAVDRYFRVPHPHALNKISNRTAAIISCLLWGTTIGLTVHLLKKKMPIONGGANLCSSF 180  
Db 121 VAVDRYFRVPHPHALNKISNRTAAIISCLLWGTTIGLTVHLLKKKMPIONGGANLCSSF 180

Qy 181 SICTFOWHEAMFLEFFPLGLIFCSARIISLRLQRQMDRHAHAKIKRAITFIMVVAIVF 240  
Db 181 SICTFOWHEAMFLEFFPLGLIFCSARIISLRLQRQMDRHAHAKIKRAITFIMVVAIVF 240

Qy 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSTFTYNSMLDPVVYFSSPS 300  
Db 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSTFTYNSMLDPVVYFSSPS 300

Qy 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360  
Db 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360

Qy 361 TSNNHKKKGCHQBPASLEKOLGCCIE 387  
Db 361 TSNNHKKKGCHQBPASLEKOLGCCIE 387

RESULT 11  
US-10-225-567A-281  
; Sequence 281, Application US/10225567A  
; Publication No. US20030113798A1  
; GENERAL INFORMATION:  
; APPLICANT: LifeSpan Biosciences  
; APPLICANT: Brown, Joseph P.  
; APPLICANT: Burmer, Glenn C.  
; APPLICANT: Roush, Christine L.  
; TITLE OF INVENTION: ANTIGENIC PEPTIDES AND ANTIBODIES FOR G PROTEIN-COUPLED RECEPTORS  
; FILE REFERENCE: 1920-4-4  
; CURRENT APPLICATION NUMBER: US/10/225,567A  
; CURRENT FILING DATE: 2001-12-19  
; PRIOR FILING DATE: 60/257,144  
; NUMBER OF SEQ ID NOS: 2292  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 281  
; LENGTH: 387  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-225-567A-281

Query Match 95.6%; Score 1990; DB 14; Length 387;  
Best Local Similarity 95.9%; Pred. No. 8e-171;  
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

Qy 1 MNRHLLQDHFLEIDKKNCCVFRDDFIKVLPPVLGLFIFGLLGNGLALWIFCFHLKSWK 60  
Db 1 MNRHLLQDHFLEIDKKNCCVFRDDFIKVLPPVLGLFIFGLLGNGLALWIFCFHLKSWK 60

Qy 61 SSRIFLENLAVADPELLIICLPFLMDNVYRRWDKFGDIPCLRLMFLMLAMNRQGSIIIFLTV 120  
Db 61 SSRIFLENLAVADPELLIICLPFLMDNVYRRWDKFGDIPCLRLMFLMLAMNRQGSIIIFLTV 120

Qy 121 VAVDRYFRVPHPHALNKISNRTAAIISCLLWGTTIGLTVHLLKKKMPIONGGANLCSSF 180  
Db 121 VAVDRYFRVPHPHALNKISNRTAAIISCLLWGTTIGLTVHLLKKKMPIONGGANLCSSF 180

Qy 181 SICTFOWHEAMFLEFFPLGLIFCSARIISLRLQRQMDRHAHAKIKRAITFIMVVAIVF 240  
Db 181 SICTFOWHEAMFLEFFPLGLIFCSARIISLRLQRQMDRHAHAKIKRAITFIMVVAIVF 240

Qy 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSTFTYNSMLDPVVYFSSPS 300  
Db 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSTFTYNSMLDPVVYFSSPS 300

Qy 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360  
Db 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPMSPSYLGP 360

Qy 361 TSNNHKKKGCHQBPASLEKOLGCCIE 387  
Db 361 TSNNHKKKGCHQBPASLEKOLGCCIE 387

```

QY 181 SICHTFQWHEAMFLLEFFLPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
DB 181 SICHTFRWHEAMFLLEFFLPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
QY 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFFITLSFTYMNMLDPVVYYFSSPS 300
DB 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFFITLSFTYMNMLDPVVYYFSSPS 300
QY 301 FPNFFSTLINRCLQRKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSYILGP 360
DB 301 FPNFFSTLINRCLQRKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSYILGP 360
QY 361 TSNNHKKGHCHQEPASLEKQLGCCIE 387
DB 361 TSNNHKKGHCHQEPASLEKQLGCCIE 387

RESULT 12
US-10-296-223-4
; Sequence 4, Application US/10296223
; Publication No. US20030139343A1
; GENERAL INFORMATION:
; APPLICANT: Bayer AG
; TITLE OF INVENTION: REGULATION OF HUMAN HM74-LIKE G PROTEIN COUPLED RECEPTOR
; FILE REFERENCE: Lio 080 foreign countries
; CURRENT APPLICATION NUMBER: US/10/296,223
; PRIOR FILING DATE: 2002-12-04
; PRIOR APPLICATION NUMBER: 60/208,912
; PRIOR FILING DATE: 2000-06-05
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
; LENGTH: 387
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-296-223-4

```

```

Query Match 95.6%; Score 1990; DB 14; Length 387;
Best Local Similarity 95.9%; Pred. No. 8e-171;
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

QY 1 MNRHHLDQHFLEIDKKNCCVFRDDFIKVLPPVLGLEFIPLGLNGLALWIFCFHLKSWK 60
DB 1 MNRHHLDQHFLEIDKKNCCVFRDDFIKVLPPVLGLEFIPLGLNGLALWIFCFHLKSWK 60
QY 61 SSRIFLNLAVADFLIICLPFLMDNYVRRDWKFGDIPCRLLMFLMANNRQGSIIPLTV 120
DB 61 SSRIFLNLAVADFLIICLPFLMDNYVRRDWKFGDIPCRLLMFLMANNRQGSIIPLTV 120
QY 121 VAVDRYFRVVPVPHALNKISNRTAAIISCLLWGITTGLTVHLLKKKMPITQNGGANLCSF 180
DB 121 VAVDRYFRVVPVPHALNKISNRTAAIISCLLWGITTGLTVHLLKKKMPITQNGGANLCSF 180
QY 181 SICHTFQWHEAMFLLEFFLPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
DB 181 SICHTFRWHEAMFLLEFFLPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
QY 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFFITLSFTYMNMLDPVVYYFSSPS 300
DB 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFFITLSFTYMNMLDPVVYYFSSPS 300
QY 301 FPNFFSTLINRCLQRKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSYILGP 360
DB 301 FPNFFSTLINRCLQRKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSYILGP 360
QY 361 TSNNHKKGHCHQEPASLEKQLGCCIE 387
DB 361 TSNNHKKGHCHQEPASLEKQLGCCIE 387

, RESULT 13

```

```

US-10-348-083-3
; Sequence 3, Application US/10348083
; Publication No. US20030186873A1
; GENERAL INFORMATION:
; APPLICANT: EISHINGDELO, Haifeng
; APPLICANT: CAI, Jidong
; APPLICANT: SANDRASAGRA, Anthony
; TITLE OF INVENTION: NUCLEIC ACID ENCODING A G-PROTEIN COUPLED RECEPTOR, AND USES THEREOF
; FILE REFERENCE: USAV2001/0054 US NP
; CURRENT APPLICATION NUMBER: US/10/348,083
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US 06/351,001
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: GB 0210597.1
; PRIOR FILING DATE: 2002-05-09
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3
; LENGTH: 387
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-348-083-3

Query Match 95.6%; Score 1990; DB 14; Length 387;
Best Local Similarity 95.9%; Pred. No. 8e-171;
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

QY 1 MNRHHLDQHFLEIDKKNCCVFRDDFIKVLPPVLGLEFIPLGLNGLALWIFCFHLKSWK 60
DB 1 MNRHHLDQHFLEIDKKNCCVFRDDFIKVLPPVLGLEFIPLGLNGLALWIFCFHLKSWK 60
QY 61 SSRIFLNLAVADFLIICLPFLMDNYVRRDWKFGDIPCRLLMFLMANNRQGSIIPLTV 120
DB 61 SSRIFLNLAVADFLIICLPFLMDNYVRRDWKFGDIPCRLLMFLMANNRQGSIIPLTV 120
QY 121 VAVDRYFRVVPVPHALNKISNRTAAIISCLLWGITTGLTVHLLKKKMPITQNGGANLCSF 180
DB 121 VAVDRYFRVVPVPHALNKISNRTAAIISCLLWGITTGLTVHLLKKKMPITQNGGANLCSF 180
QY 181 SICHTFQWHEAMFLLEFFLPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
DB 181 SICHTFRWHEAMFLLEFFLPLGLIILFCSARIISLQRQMDRHAQIKRAITFTIMVAIVF 240
QY 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFFITLSFTYMNMLDPVVYYFSSPS 300
DB 241 VICFLPSVVVRIIRIFWLLHTSGTQNCVYRSVDLAFFITLSFTYMNMLDPVVYYFSSPS 300
QY 301 FPNFFSTLINRCLQRKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSYILGP 360
DB 301 FPNFFSTLINRCLQRKMTGPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSYILGP 360
QY 361 TSNNHKKGHCHQEPASLEKQLGCCIE 387
DB 361 TSNNHKKGHCHQEPASLEKQLGCCIE 387

RESULT 14
US-10-044-643-43
; Sequence 43, Application US/10044643
; Publication No. US20030195335A1
; GENERAL INFORMATION:
; APPLICANT: Majumder, Kumud
; APPLICANT: Vernet, Corine
; APPLICANT: Casman, Stacie J
; APPLICANT: Wolenc, Adam R
; APPLICANT: Spaderna, Steven K
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Mishnu, Vishnu S
; APPLICANT: Tchernev, Velizar T
; APPLICANT: Spytek, Kimberly A
; APPLICANT: Li, Li
; APPLICANT: Baumgartner, Jason C
; APPLICANT: Gusev, Vladimir

```



; TITLE OF INVENTION: No. US20030195335a1el Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 15966-748
; CURRENT APPLICATION NUMBER: US/10/044,643
; CURRENT FILING DATE: 2002-01-11
; PRIOR APPLICATION NUMBER: 60/193,664
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: 60/194,614
; PRIOR FILING DATE: 2000-04-05
; PRIOR APPLICATION NUMBER: 60/195,063
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 60/195,066
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 60/195,067
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 60/195,068
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 60/195,069
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 60/195,070
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 60/195,510
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 60/219,855
; PRIOR FILING DATE: 2000-07-21
; PRIOR APPLICATION NUMBER: 60/221,284
; PRIOR FILING DATE: 2000-07-27
; PRIOR APPLICATION NUMBER: 60/221,325
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 60/224,588
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/239,613
; PRIOR FILING DATE: 2000-10-11
; PRIOR APPLICATION NUMBER: 60/262,508
; PRIOR FILING DATE: 2001-01-18
; PRIOR APPLICATION NUMBER: 60/263,604
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 60/263,433
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 60/265,161
; PRIOR FILING DATE: 2001-01-30
; NUMBER OF SEQ ID NOS: 83
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 43
; LENGTH: 387
; TYPE: PR1
; ORGANISM: Homo sapiens
US-10-044-643-43

Query Match 95.6%; Score 1990; DB 14; Length 387;
Best Local Similarity 95.9%; Pred. No. 8e-171;
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

Qy 1 MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVGLGFIFGLLGNGLALWIFCFHLKSWK 60
Db 1 MNRHLLQDHFLEIDKKNCCVFRDDFIAKVLPPVGLGFIFGLLGNGLALWIFCFHLKSWK 60

Qy 61 SSRIFLNLAVADFLIIICLPFLMDNVYVRWDKFGDIPCLMLFMLAMNRQSGIIFLTV 120
Db 61 SSRIFLNLAVADFLIIICLPFLMDNVYVRWDKFGDIPCLMLFMLAMNRQSGIIFLTV 120

Qy 121 VAVDRYFRVVPVPHALNKISNRATAIISCLLWGITIGLTVHLLKKKMPIONGGANLCSF 180
Db 121 VAVDRYFRVVPVPHALNKISNRATAIISCLLWGITIGLTVHLLKKKLIQNGPANVCISF 180

Qy 181 SICTFOWHEAMFLFELFPLGILFCSARIINSRORQDRHAKIKRAITFMVAIVF 240
Db 181 SICTFOWHEAMFLFELFPLGILFCSARIINSRORQDRHAKIKRAITFMVAIVF 240

Qy 241 VICFLPSVVVRIIRIFWLLHSTSGTQNCVYRSVDLAFITLSFTYMSMLDPVYVYFSSPS 300
Db 241 VICFLPSVVVRIIRIFWLLHSTSGTQNCVYRSVDLAFITLSFTYMSMLDPVYVYFSSPS 300

Qy 301 FPNFFSTLINRCLQKWKGTGPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSVYLG 360

Db 301 FPNFFSTLINRCLQKWKGTGPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSVYLG 360
Qy 361 TSNHSHKKGCHQEPASLEKQLGCCIE 387
Db 361 TSNHSHKKGCHQEPASLEKQLGCCIE 387

RESULT 15
US-10-295-027-228
; Sequence 228, Application US/10295027
; Publication No. US20030232350A1
; GENERAL INFORMATION:
; APPLICANT: Afar, Daniel
; APPLICANT: Aziz, Natasha
; APPLICANT: Ginsberg, Wendy M.
; APPLICANT: Gish, Kurt C.
; APPLICANT: Glynn, Richard
; APPLICANT: Hevezi, Peter A.
; APPLICANT: Mack, David H.
; APPLICANT: Murray, Richard
; APPLICANT: Watson, Susan R.
; APPLICANT: Eos Biotechnology, Inc.
; TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and
; TITLE OF INVENTION: Methods of Screening for Modulators of Cancer
; FILE REFERENCE: 018501-012500US
; CURRENT APPLICATION NUMBER: US/10/295,027
; CURRENT FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: US 09/663,733
; PRIOR FILING DATE: 2000-09-15
; PRIOR APPLICATION NUMBER: US 60/350,666
; PRIOR FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: US 60/335,394
; PRIOR FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: US 60/332,464
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: US 60/334,393
; PRIOR FILING DATE: 2001-11-29
; PRIOR APPLICATION NUMBER: US 60/340,376
; PRIOR FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: US 60/347,211
; PRIOR FILING DATE: 2002-01-08
; PRIOR APPLICATION NUMBER: US 60/347,349
; PRIOR FILING DATE: 2002-01-10
; PRIOR APPLICATION NUMBER: US 60/355,250
; PRIOR FILING DATE: 2002-02-08
; PRIOR APPLICATION NUMBER: US 60/356,714
; PRIOR FILING DATE: 2002-02-13
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1386
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 228
; LENGTH: 387
; TYPE: PR1
; ORGANISM: Homo sapiens
US-10-295-027-228

Query Match 95.6%; Score 1990; DB 15; Length 387;
Best Local Similarity 95.9%; Pred. No. 8e-171;
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

Qy 1 MNRHLLQDHFLEIDKKNCCVFRDDFIVKVLPPVGLGFIFGLLGNGLALWIFCFHLKSWK 60
Db 1 MNRHLLQDHFLEIDKKNCCVFRDDFIAKVLPPVGLGFIFGLLGNGLALWIFCFHLKSWK 60

Qy 61 SSRIFLNLAVADFLIIICLPFLMDNVYVRWDKFGDIPCLMLFMLAMNRQSGIIFLTV 120
Db 61 SSRIFLNLAVADFLIIICLPFLMDNVYVRWDKFGDIPCLMLFMLAMNRQSGIIFLTV 120

Qy 121 VAVDRYFRVVPVPHALNKISNRATAIISCLLWGITIGLTVHLLKKKMPIONGGANLCSF 180
Db 121 VAVDRYFRVVPVPHALNKISNRATAIISCLLWGITIGLTVHLLKKKLIQNGPANVCISF 180

QY	181	SICHTFQWHEAMFLLLEFFPLGLIILFCSARI IWSLRQROMDRHAKIKRAITFIMVVAIVF	240
Db	181	SICHTFRWHEAMFLLLEFFPLGLIILFCSARI IWSLRQROMDRHAKIKRAITFIMVVAIVF	240
QY	241	VICFLPSVVVRIRIFWLLHTSGTQNCCEVYRSVDLAFFITLSFTYMNMLDPVVYFYSSPS	300
Db	241	VICFLPSVVVRIRIFWLLHTSGTQNCCEVYRSVDLAFFITLSFTYMNMLDPVVYFYSSPS	300
QY	301	FPNFFSTLINRCLQRKMTGEPDNNRSTVELTGDPNKTRGAPEALMANSGEPMSPSYLGP	360
Db	301	FPNFFSTLINRCLQRKMTGEPDNNRSTVELTGDPNKTRGAPEALMANSGEPMSPSYLGP	360
QY	361	TSNNHSGKGHCHEPASLEKQLGCCIE	387
Db	361	TSNNHSGKGHCHEPASLEKQLGCCIE	387

Search completed: October 20, 2005, 07:52:41  
 Job time : 4755 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 20, 2005, 06:00:16 ; Search time 22 Seconds  
(without alignments)  
1313.145 Million cell updates/sec

Title: US-10-800-249-2  
Perfect score: 2081  
Sequence: 1 MNRHLLQDHLEIDKKNCCV.....KGHCHOEPASLEKQLGCCIE 387

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued Patents AA:\*  
1: /cgn2\_6/ptodata/1/iaa/5A\_COMB.pep.\*  
2: /cgn2\_6/ptodata/1/iaa/5B\_COMB.pep.\*  
3: /cgn2\_6/ptodata/1/iaa/6A\_COMB.pep.\*  
4: /cgn2\_6/ptodata/1/iaa/6B\_COMB.pep.\*  
5: /cgn2\_6/ptodata/1/iaa/PCTUS\_COMB.pep.\*  
6: /cgn2\_6/ptodata/1/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1990	95.6	387	4	US-09-170-496D-108
2	1990	95.6	387	4	US-09-944-807-21
3	1988	95.5	387	4	US-09-170-496D-222
4	563	27.1	423	2	US-08-955-713-2
5	559	26.9	476	2	US-08-955-713-4
6	497.5	23.9	319	3	US-09-130-749-2
7	497.5	23.9	319	3	US-09-130-749-2
8	494.5	23.8	319	4	US-09-170-496D-60
9	494.5	23.8	319	4	US-09-170-496D-196
10	427	20.5	362	3	US-08-513-974B-374
11	415	19.9	373	2	US-08-559-524A-4
12	415	19.9	373	3	US-08-749-707-4
13	415	19.9	373	4	US-09-947-922-4
14	407	19.6	373	4	US-09-745-842-14
15	375.5	18.0	309	3	US-09-422-869-20
16	370.5	17.8	346	4	US-09-585-876-2
17	368	17.7	374	4	US-09-745-842-15
18	353.5	17.0	370	3	US-08-781-250-2
19	350.5	16.8	364	4	US-08-148-708-2
20	350	16.8	339	1	US-08-153-848-44
21	350	16.8	339	2	US-08-812-871-3
22	350	16.8	339	3	US-09-299-843A-44
23	350	16.8	339	3	US-09-088-337B-44
24	350	16.8	339	4	US-09-170-496D-32
25	350	16.8	339	5	PCT-US93-11153-44
26	350	16.8	339	5	PCT-US95-07180-2
27	348.5	16.7	391	4	US-09-826-509-463

ALIGNMENTS

RESULT 1

US-09-170-496D-108

; Sequence 108, Application US/09170496D

; Patent No. 6555339

; GENERAL INFORMATION:

; APPLICANT: Behan, Dominic P.

; APPLICANT: Chalmers, Derek T.

; APPLICANT: Liaw, Chen W.

; TITLE OF INVENTION: No. 6555339-Endogenous, Constitutively Activated Human G Protein-

; FILE REFERENCE: AREN-0040

; CURRENT APPLICATION NUMBER: US/09/170,496D

; CURRENT FILING DATE: 1998-10-13

; NUMBER OF SEQ ID NOS: 294

; SOFTWARE: Patentin version 3.1

; SEQ ID NO 108

; LENGTH: 387

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-170-496D-108

Query Match 95.6%; Score 1990; DB 4; Length 387;  
Best Local Similarity 95.9%; Pred. No. 1.1e-164;  
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

Qy	1	MNRHLLQDHLEIDKKNCCVFRDDPIVKVLPVVLGLEFIFGLLGNGLALMIFCFHLKSWK	60
Db	1	MNRHLLQDHLEIDKKNCCVFRDDPIAKVLPVVLGLEFIFGLLGNGLALMIFCFHLKSWK	60
Qy	61	SSRIFENLAVADFLIICLPFLMDNVYRRWDKFGDIPCLRMLFMLANRQGSIIFLT	120
Db	61	SSRIFENLAVADFLIICLPFLMDNVYRRWDKFGDIPCLRMLFMLANRQGSIIFLT	120
Qy	121	VAVDRYRVVPHHALNKISNRNTAAITISCLLWGTTIGLTVHLLKKKMPIONGGANLCSFP	180
Db	121	VAVDRYRVVPHHALNKISNRNTAAITISCLLWGTTIGLTVHLLKKKMPIONGGANLCSFP	180
Qy	181	SICHTFOWHEAMLEFFELPLGILFCSARIINSLRQMDRHAHAKIKRAITFIWVAIVF	240
Db	181	SICHTFOWHEAMLEFFELPLGILFCSARIINSLRQMDRHAHAKIKRAITFIWVAIVF	240
Qy	241	VICFLPSVVVRIRIFWLLHSTSGTNCVYRSVDLAFFITLSFTYMNMLDPVVIYFSSPS	300
Db	241	VICFLPSVVVRIRIFWLLHSTSGTNCVYRSVDLAFFITLSFTYMNMLDPVVIYFSSPS	300
Qy	301	FPNFFSTLINRCLQRKMTGPDNNRSTVELTDPNKTGRGAPEALMANSGEWPSYLG	360
Db	301	FPNFFSTLINRCLQRKMTGPDNNRSTVELTDPNKTGRGAPEALMANSGEWPSYLG	360
Qy	361	TSNNHKKGHCHQEPASLEKQLGCCIE	387

```
Db 361 TSNHSHKKGCHQEPASLEKQLGCCIE 387
|||||
RESULT 2
US-09-944-807-21
; Sequence 21, Application US/09944807
; Patent No. 6773895
; GENERAL INFORMATION:
; APPLICANT: Boehringer Ingelheim Pharma KG
; TITLE OF INVENTION: Method for identifying substances which positively
; TITLE OF INVENTION: influence inflammatory conditions of chronic
; TITLE OF INVENTION: inflammatory airway diseases
; FILE REFERENCE: 082.00n
; CURRENT APPLICATION NUMBER: US/09/944, 807
; CURRENT FILING DATE: 2001-08-31
; PRIOR APPLICATION NUMBER: UK 0021484.1
; PRIOR FILING DATE: 2000-09-01
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-944-807-21

Query Match 95.6%; Score 1990; DB 4; Length 387;
Best Local Similarity 95.9%; Pred. No. 1.1e-164;
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

QY 1 MNRHLLQDHLEIDKKNCCVFRDDFIVKVLPPVGLGFIPLGLGNGLALWIFCFHLKSWK 60
DB 1 MNRHLLQDHLEIDKKNCCVFRDDFIAKVLPPVGLGFIPLGLGNGLALWIFCFHLKSWK 60
QY 61 SSRIFLNLAVADFLIICLPFLMDNYVRWDKFGDIPCLRLMFLMAMNRQGSIIFLT 120
DB 61 SSRIFLNLAVADFLIICLPFLMDNYVRWDKFGDIPCLRLMFLMAMNRQGSIIFLT 120
QY 121 VAVDRYFRVPHALNKISNRTAAIISCLLWGITVGLTVHLLKKKMPIONGGANLCSSF 180
DB 121 VAVDRYFRVPHALNKISNRTAAIISCLLWGITVGLTVHLLKKKMPIONGGANLCSSF 180
QY 181 SICTFOWHEAMFLLEFFPLGLIIFCSARIISLRQMDRHAQIKRAITFMVVAIVF 240
DB 181 SICTFOWHEAMFLLEFFPLGLIIFCSARIISLRQMDRHAQIKRAITFMVVAIVF 240
QY 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMLDPVVVYFSSPS 300
DB 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMLDPVVVYFSSPS 300
QY 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSYLG 360
DB 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSYLG 360
QY 361 TSNHSHKKGCHQEPASLEKQLGCCIE 387
DB 361 TSNHSHKKGCHQEPASLEKQLGCCIE 387

RESULT 3
US-09-170-496D-222
; Sequence 22, Application US/09170496D
; Patent No. 6555339
; GENERAL INFORMATION:
; APPLICANT: Behan, Dominic P.
; APPLICANT: Chalmers, Derek T.
; APPLICANT: Liao, Chen W.
; TITLE OF INVENTION: No. 6555339-Endogenous, Constitutively Activated Human G Protein-
; FILE REFERENCE: AREN-0040
; CURRENT APPLICATION NUMBER: US/09/170,496D
; CURRENT FILING DATE: 1998-10-13
; NUMBER OF SEQ ID NOS: 294
```

```
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 222
; LENGTH: 387
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-170-496D-222

Query Match 95.5%; Score 1988; DB 4; Length 387;
Best Local Similarity 95.9%; Pred. No. 1.6e-164;
Matches 371; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

QY 1 MNRHLLQDHLEIDKKNCCVFRDDFIVKVLPPVGLGFIPLGLGNGLALWIFCFHLKSWK 60
DB 1 MNRHLLQDHLEIDKKNCCVFRDDFIAKVLPPVGLGFIPLGLGNGLALWIFCFHLKSWK 60
QY 61 SSRIFLNLAVADFLIICLPFLMDNYVRWDKFGDIPCLRLMFLMAMNRQGSIIFLT 120
DB 61 SSRIFLNLAVADFLIICLPFLMDNYVRWDKFGDIPCLRLMFLMAMNRQGSIIFLT 120
QY 121 VAVDRYFRVPHALNKISNRTAAIISCLLWGITVGLTVHLLKKKMPIONGGANLCSSF 180
DB 121 VAVDRYFRVPHALNKISNRTAAIISCLLWGITVGLTVHLLKKKMPIONGGANLCSSF 180
QY 181 SICTFOWHEAMFLLEFFPLGLIIFCSARIISLRQMDRHAQIKRAITFMVVAIVF 240
DB 181 SICTFOWHEAMFLLEFFPLGLIIFCSARIISLRQMDRHAQIKRAITFMVVAIVF 240
QY 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMLDPVVVYFSSPS 300
DB 241 VICFLPSVVVIRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMLDPVVVYFSSPS 300
QY 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSYLG 360
DB 301 FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPSYLG 360
QY 361 TSNHSHKKGCHQEPASLEKQLGCCIE 387
DB 361 TSNHSHKKGCHQEPASLEKQLGCCIE 387

RESULT 4
US-08-955-713-2
; Sequence 2, Application US/08955713
; Patent No. 5955308
; GENERAL INFORMATION:
; APPLICANT: SATHE, GANESH
; APPLICANT: MOONEY, JEFFREY
; APPLICANT: BERGMA, DERK
; APPLICANT: HALSEY, WENDY
; TITLE OF INVENTION: CDNA CLONE HEOAD54 THAT ENCODES A HUMAN 7-TRANS
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: RATNER & PRESTIA
; STREET: P.O. BOX 980
; CITY: VALLEY FORGE
; STATE: PA
; COUNTRY: USA
; ZIP: 19482
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/955,713
; FILING DATE: 23-OCT-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: 60/050,124
; APPLICATION NUMBER:
; FILING DATE: 18-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: PRESTIA, PAUL F
; REGISTRATION NUMBER: 23,031
```

```
; REFERENCE/DOCKET NUMBER: GH-70087
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 610-407-0700
; TELEFAX: 610-407-0701
; TELEX: 846169
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 423 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-955-713-2

Query Match      27.1%; Score 563; DB 2; Length 423;
Best Local Similarity 41.8%; Pred. No. 6.7e-41;
Matches 118; Conservative 52; Mismatches 88; Indels 24; Gaps 5;

QY 30 LPPVLGHEFIFGLGNGALWIFCFHLKSKWSKSRIFLNLAVADFLIICLPFLMDNVVR 89
DQ 95 LAPILALEFVLGVLGNSLALFICFHTRPMTSNTVFLVSLVAADFLIISNLPLRVYLL 154
QY 90 RWDKFGDIPCRMLFMLAMNRQGSIIFLTVAVDVRVYVPHHAKLNKISNRTAAIISC 149
DQ 155 HETWRFGAACKVNLFWLSTNRTASVFLTAIALNRYLVKVVPHVLSRASVGAAARVAG 214
QY 150 LLGMITGLTVHLKKKMPIONGGANLCSSFSI-----CHTFQWHEAMFLLEFFPLGLIIL 205
DQ 215 GLWVGILLNGHLL-----LSTFGSPCLSYRVGTPKPSASLRWHQALYLLLEFFPLALIL 269
QY 206 FCSARIISLRQQRMDRHAKIKRAITFMVAVIVFICFLPSVY---VRIRIFWLLHTSG 262
DQ 270 FAIVSIGLITRNRLGGLGQAGQARMVAVVYITICFLPSIFGMSAVAFWL----- 324
QY 263 TQNCVYRSVDLA---FFITLSFTYMSMLDPVYVYFSSPSF 301
DQ 325 ----SACRSIDLCTQLFHGSLAFTYLSVLDPLVLYCFSSPNF 362

RESULT 5
US-08-955-713-4
; Sequence 4, Application US/08955713
; Patent No. 595308
; GENERAL INFORMATION:
; APPLICANT: SATHE, GANESH
; APPLICANT: MOONEY, JEFFREY
; APPLICANT: BERGSMAN, DEK
; APPLICANT: HALSEY, WENDY
; TITLE OF INVENTION: CDNA CLONE HE04D54 THAT ENCODES A HUMAN 7-TRANS
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: RATNER & PRESTIA
; STREET: P.O. BOX 980
; CITY: VALLEY, FORGE
; STATE: PA
; COUNTRY: USA
; ZIP: 19482
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/955,713
; FILING DATE: 23-OCT-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/050,124
; FILING DATE: 18-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: PRESTIA, PAUL F
; REGISTRATION NUMBER: 23,031
; REFERENCE/DOCKET NUMBER: GH-70087

; REFERENCE/DOCKET NUMBER: GH-70087
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 610-407-0700
; TELEFAX: 610-407-0701
; TELEX: 846169
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 476 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-955-713-4

Query Match      26.9%; Score 559; DB 2; Length 476;
Best Local Similarity 41.5%; Pred. No. 1.7e-40;
Matches 117; Conservative 53; Mismatches 88; Indels 24; Gaps 6;

QY 30 LPPVLGHEFIFGLGNGALWIFCFHLKSKWSKSRIFLNLAVADFLIICLPFLMDNVVR 89
DQ 6 LAPILALEFVLGVLGNSLALFICFHTRPMTSNTVFLVSLVAADFLIISNLPLRVYLL 65
QY 90 RWDKFGDIPCRMLFMLAMNRQGSIIFLTVAVDVRVYVPHHAKLNKISNRTAAIISC 149
DQ 66 HETWRFGAACKVNLFWLSTNRTASVFLTAIALNRYLVKVVPHVLSRASVGAAARVX- 124
QY 150 LLGMITGLTVHLKKKMPIONGGANLCSSFSI-----CHTFQWHEAMFLLEFFPLGLIIL 205
DQ 125 --GGIWWGIL--LLNGXLLLTFTSPCLSYRVGTPKPSASLRWHQALYLLLEFFPLALIL 180
QY 206 FCSARIISLRQQRMDRHAKIKRAITFMVAVIVFICFLPSVY---VRIRIFWLLHTSG 262
DQ 181 FAIVSIGLITRNRLGGLGQAGQARMVAVVYITICFLPSIFGMSAVAFWL----- 235
QY 263 TQNCVYRSVDLA---FFITLSFTYMSMLDPVYVYFSSPSF 301
DQ 236 ----SACRSIDLCTQLFHGSLAFTYLSVLDPLVLYCFSSPNF 273

RESULT 6
US-09-130-749-2
; Sequence 2, Application US/09130749
; Patent No. 6031090
; GENERAL INFORMATION:
; APPLICANT: SHABON, USMAN
; APPLICANT: ELSHOURBAGY, NABIL
; TITLE OF INVENTION: MOLECULAR CLONING OF A 7TM
; RECEPTOR (GPR31A)
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: RATNER & PRESTIA
; STREET: P.O. Box 980
; CITY: Valley Forge
; STATE: PA
; COUNTRY: USA
; ZIP: 19482
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/130,749
; FILING DATE: 07-Aug-1998
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: <Unknown>
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: PRESTIA, PAUL F
; REGISTRATION NUMBER: 23,031
; REFERENCE/DOCKET NUMBER: GP-70513
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 610-407-0700
```



Db 80 WHLRGVCWALRFLDLRSVGMAFLAAVALDRYLRVPHRLKVNLLSPQAALGVSLVW 139  
Qy 153 GITIGLTVHLLKKKMPITQNGANLCSSFSICHTFQ-----WHEAMFLLEFFFLPLG 202  
Db 140 LLWVALTCPLLISEAQN-----TRCHSFYSRADGSGFSIIWQEALSCLOFVLFPFG 191  
Qy 203 IILFCARITWSL--RORQMDRAHAKIKRAITFMVVAIVFICPLPSVVVRIIFWLLHT 260  
Db 192 LIVFCNAGITRALQKRLREPEKQKLOQAALVTLVVVLFALCPLCPFLARV----LWHI 247  
Qy 261 -SGTQNCVRSVDLAFITLSTFYMNSMLDPVVVYFSSPFPNFFSTLINRCLQRKWTG 319  
Db 248 FQNLGSCRALCAVAHSDVTGSLTYLHSVNVVPCFSSPTFRSSYRRVFTLRLRGQAA 307  
Qy 320 EP 321  
Db 308 EP 309  
RESULT 9  
US-09-170-496D-196  
; Sequence 196, Application US/09170496D  
; Patent No. 655339  
; GENERAL INFORMATION:  
; APPLICANT: Behan, Dominic P.  
; APPLICANT: Chalmers, Derek T.  
; APPLICANT: Liaw, Chen W.  
; TITLE OF INVENTION: No. 655339-Endogenous, Constitutively Activated Human G Protein-  
; TITLE OF INVENTION: Receptors  
; FILE REFERENCE: AREN-0040  
; CURRENT APPLICATION NUMBER: US/09/170,496D  
; CURRENT FILING DATE: 1998-10-13  
; NUMBER OF SEQ ID NOS: 294  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 196  
; LENGTH: 319  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-170-496D-196  
Query Match 23.8%; Score 494.5; DB 4; Length 319;  
Best Local Similarity 36.1%; Pred. No. 4.3e-35;  
Matches 109; Conservative 57; Mismatches 111; Indels 25; Gaps 5;  
Qy 33 VLGLEFTFGLLGNGLALWIFCFHLKSWKSRIFLNFNLAVADFLLIICLPFLMDNYVRWD 92  
Db 20 LLGLECGLLGNVAVALTWTLFRVWVKPYAVYLLNLALADLLLAACPLFLAFYLSLOA 79  
Qy 93 WKFGDIPCRMLMFLMAMNQGSIIFLTVAVDYRVVPHPHALNKISNRATAIISCLLW 152  
Db 80 WHLRGVCWALRFLDLRSVGMAFLAAVALDRYLRVPHRLKVNLLSPQAALGVSLVW 139  
Qy 153 GITIGLTVHLLKKKMPITQNGANLCSSFSICHTFQ-----WHEAMFLLEFFFLPLG 202  
Db 140 LLWVALTCPLLISEAQN-----TRCHSFYSRADGSGFSIIWQEALSCLOFVLFPFG 191  
Qy 203 IILFCARITWSL--RORQMDRAHAKIKRAITFMVVAIVFICPLPSVVVRIIFWLLHT 260  
Db 192 LIVFCNAGITRALQKRLREPEKQKLOQAALVTLVVVLFALCPLCPFLARV----LWHI 247  
Qy 261 -SGTQNCVRSVDLAFITLSTFYMNSMLDPVVVYFSSPFPNFFSTLINRCLQRKWTG 319  
Db 248 FQNLGSCRALCAVAHSDVTGSLTYLHSVNVVPCFSSPTFRSSYRRVFTLRLRGQAA 307  
Qy 320 EP 321  
Db 308 EP 309  
RESULT 10  
US-08-513-974B-374  
; Sequence 374, Application US/08513974B

; Patent No. 6114139  
; GENERAL INFORMATION:  
; APPLICANT: Hinuma, Shuji  
; APPLICANT: Hosoya, Masaki  
; APPLICANT: Fujii, Ryo  
; APPLICANT: Ohtaki, Tetsuya  
; APPLICANT: Fukusumi, Shoji  
; APPLICANT: Ohgi, Kazuhito  
; TITLE OF INVENTION: G PROTEIN COUPLED RECEPTOR PROTEIN,  
; TITLE OF INVENTION: PRODUCTION, AND USE THEREOF  
; NUMBER OF SEQUENCES: 380  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP  
; STREET: 130 Water Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA: US/08/513,974B  
; APPLICATION NUMBER: 14-SEP-1995  
; CLASSIFICATION: 536  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: PCT/JP95/01599  
; FILING DATE: 10-AUG-1995  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: JP 7-093989  
; FILING DATE: 19-AUG-1995  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: JP 7-057186  
; FILING DATE: 16-MAR-1995  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: JP 7-007177  
; FILING DATE: 20-JAN-1995  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: JP 6-326611  
; FILING DATE: 28-DEC-1994  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: JP 6-270017  
; FILING DATE: 02-NOV-1994  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: JP 6-236357  
; FILING DATE: 30-SEP-1994  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: JP 6-236356  
; FILING DATE: 30-SEP-1994  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: JP 6-189274  
; FILING DATE: 11-AUG-1994  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: JP 6-189273  
; FILING DATE: 11-AUG-1994  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: JP 6-189272  
; FILING DATE: 11-AUG-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Resnick, David S.  
; REGISTRATION NUMBER: 34,235  
; REFERENCE/DOCKET NUMBER: 45753  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-523-3400  
; TELEFAX: 617-523-6440  
; INFORMATION FOR SEQ ID NO: 374:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 362 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear





```
QY 18 CCVRDDFIVKVLPPVLGLFIFGLLGNGLALWIFCFHLKSWKSSRIFFLNFNLAVADFLI 77
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 42 CALTKTGQFYFYLPAVYILVFIIGFLGNSVAIWMFVFMKPSGSIYVMFNLAADFLYV 101
QY 78 ICLPFLMDNVRRWDWKFGDIPCLRLMLFMLAMNRQGSIIFLTVAVDYFRVVPHPHALN 137
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 102 LTLPALIFYFNKTDWIFGDAMCKLQRFIFHVNLYGSILFUTCISAHRYSGVVPKLSLG 161
QY 138 KISNRATAIISCLLWGI-TIGLTVHLLKKKMPIONGGANLCS-----FSICH 184
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 162 RLKKNNAVYISVLVWLIWVGISPLIFYSGTGIRKNTITCYDTSDEYLSRYIYSMCT 221
QY 185 TFQWHEAMFLEFFPLGLIIFCSARIWISURQOMDRHAKIKRAITFIWVAIVFVICF 244
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 222 TV-----AMFC-----VPLVILGCVGLIVRALIYKDLNLSPLRRKSIYLVILTVFAVSY 273
QY 245 LPSVVVR-IRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMLDPVVVYFSPSPFN 303
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 274 IPFHVMTMNLARLDFTQPEMCAFNDRVVATYQVTRGLASLNSCVDPIFLYLAGDTFRR 333
QY 304 FFSTLINRCLQRKMTGEPDNNRSTSVELT 332
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 334 RLSRATRKASRSEA-----NLQSKSEDMT 358
```

## RESULT 13

```
US-09-947-922-4
; Sequence 4, Application US/09947922
; Patent No. 6680373
; GENERAL INFORMATION:
; APPLICANT: Conley, Pamela B.
; Jantzen, Hans-Michael
; TITLE OF INVENTION: NOVEL PURINERGIC RECEPTOR
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: MORGAN, LEWIS & BOCKIUS LLP
; STREET: 1800 M Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20036-5869
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/947,922
; FILING DATE: 07-Sep-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/749,707
; FILING DATE: 15-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Adler, Reid G.
; REGISTRATION NUMBER: 30,988
; REFERENCE/DOCKET NUMBER: 044481-5010-01-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-467-7000
; TELEFAX: 202-467-7176
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 373 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-947-922-4
```

Query Match 19.9%; Score 415; DB 4; Length 373;  
Best Local Similarity 29.8%; Pred. No. 4e-28;

```
Matches 98; Conservative 66; Mismatches 139; Indels 26; Gaps 6;
QY 18 CCVRDDFIVKVLPPVLGLFIFGLLGNGLALWIFCFHLKSWKSSRIFFLNFNLAVADFLI 77
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 42 CALTKTGQFYFYLPAVYILVFIIGFLGNSVAIWMFVFMKPSGSIYVMFNLAADFLYV 101
QY 78 ICLPFLMDNVRRWDWKFGDIPCLRLMLFMLAMNRQGSIIFLTVAVDYFRVVPHPHALN 137
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 102 LTLPALIFYFNKTDWIFGDAMCKLQRFIFHVNLYGSILFUTCISAHRYSGVVPKLSLG 161
QY 138 KISNRATAIISCLLWGI-TIGLTVHLLKKKMPIONGGANLCS-----FSICH 184
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 162 RLKKNNAVYISVLVWLIWVGISPLIFYSGTGIRKNTITCYDTSDEYLSRYIYSMCT 221
QY 185 TFQWHEAMFLEFFPLGLIIFCSARIWISURQOMDRHAKIKRAITFIWVAIVFVICF 244
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 222 TV-----AMFC-----VPLVILGCVGLIVRALIYKDLNLSPLRRKSIYLVILTVFAVSY 273
QY 245 LPSVVVR-IRIFWLLHTSGTQNCVYRSVDLAFITLSFTYMNMLDPVVVYFSPSPFN 303
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 274 IPFHVMTMNLARLDFTQPEMCAFNDRVVATYQVTRGLASLNSCVDPIFLYLAGDTFRR 333
QY 304 FFSTLINRCLQRKMTGEPDNNRSTSVELT 332
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 334 RLSRATRKASRSEA-----NLQSKSEDMT 358
```

## RESULT 14

```
US-09-745-842-14
; Sequence 14, Application US/09745842
; Patent No. 6762029
; GENERAL INFORMATION:
; APPLICANT: Conley, Pamela B.
; Jantzen, Hans-Michael
; APPLICANT: Ramakrishnan-DuBridge, Vanitha
; APPLICANT: Julius, David
; APPLICANT: Hollopetter, Gunter
; APPLICANT: COR Therapeutics, Inc.
; TITLE OF INVENTION: P2Y12 Receptor
; FILE REFERENCE: 4481-5053-US
; CURRENT APPLICATION NUMBER: US/09/745,842
; CURRENT FILING DATE: 2000-12-26
; PRIOR APPLICATION NUMBER: US 60/171,622
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 14
; LENGTH: 373
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: P2Y1 purinergic receptor; p2Yr
US-09-745-842-14
```

Query Match 19.6%; Score 407; DB 4; Length 373;  
Best Local Similarity 28.5%; Pred. No. 2e-27;  
Matches 97; Conservative 62; Mismatches 133; Indels 48; Gaps 7;

```
QY 18 CCVRDDFIVKVLPPVLGLFIFGLLGNGLALWIFCFHLKSWKSSRIFFLNFNLAVADFLI 77
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 42 CALTKTGQFYFYLPAVYILVFIIGFLGNSVAIWMFVFMKPSGSIYVMFNLAADFLYV 101
QY 78 ICLPFLMDNVRRWDWKFGDIPCLRLMLFMLAMNRQGSIIFLTVAVDYFRVVPHPHALN 137
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 102 LTLPALIFYFNKTDWIFGDAMCKLQRFIFHVNLYGSILFUTCISAHRYSGVVPKLSLG 161
QY 138 KISNRATAIISCLLWGI-TIGLTVHLLKKKMPIONGGANLCS-----FSICH 184
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 162 RLKKNNAVYISVLVWLIWVGISPLIFYSGTGIRKNTITCYDTSDEYLSRYIYSMCT 221
QY 185 TFQWHEAMFLEFFPLGLIIFCSARIWISURQOMDRHAKIKRAITFIWVAIVFVICF 244
D  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 222 TV-----AMFC-----VPLVILGCVGLIVRALIYKDLNLSPLRRKSIYLVILTVFAVSY 273
```

QY 245 LPSVVVRIRIFWLHTSGTON-----CEVRSVDLAFITLSTFTYNSMLDPV 292  
Db 274 IP-----PHVMTNRLRLDFQTPACAFNDRVYATYQVTRGLASLNSCVDFI 322  
QY 293 VYFSSPSPFNFTSLINCLQKMTGEPDNNRSTSVLT 332  
Db 323 LYFLAGDTFRRLSRATRKASRSEA----NLQSKSEDWT 358

## RESULT 15

US-09-422-869-20  
; Sequence 20, Application US/09422869  
; Patent No. 6235481  
; GENERAL INFORMATION:  
; APPLICANT: POLONSKY, KENNETH S.  
; APPLICANT: HORIKAWA, YUKIO  
; APPLICANT: ODA, NAOHISA  
; APPLICANT: COX, NANCY J.  
; APPLICANT: SREENAN, SEAMUS  
; APPLICANT: ZHOU, YUN-PING  
; APPLICANT: OTANI, KENICHI  
; APPLICANT: HANIS, CRAIG L.  
; APPLICANT: BELL, GRAEME I.  
; TITLE OF INVENTION: METHODS OF TREATMENT OF TYPE 2 DIABETES  
; FILE REFERENCE: ARCD:307  
; CURRENT APPLICATION NUMBER: US/09/422,869  
; CURRENT FILING DATE: 1999-10-21  
; EARLIER APPLICATION NUMBER: 60/134,175  
; EARLIER FILING DATE: 1999-05-13  
; NUMBER OF SEQ ID NOS: 30  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 20  
; LENGTH: 309  
; TYPE: PRT  
; ORGANISM: Human  
US-09-422-869-20

Query Match 18.0%; Score 375.5; DB 3; Length 309;  
Best Local Similarity 34.1%; Pred. No. 8.6e-25;  
Matches 94; Conservative 48; Mismatches 107; Indels 27; Gaps 10;  
QY 34 LGLEFIFGLNGLALWIFCFHLKSWKSSRIFLNLAVADFLIIICLPFLMDNYVRRWDW 93  
Db 27 LGVLLVGLLLNSLALWVFCRMOQQTETRIYNTNLAVADCLCTIPFVHSL-----R 81  
QY 94 KFGDIP-CRLMFLMANRQGSIIFTLVAVDRIYRVVPHPHALNKISNRTAAIISCLLW 152  
Db 82 DTSDTPLCQLSQGIYLTNRYSISLVTAIAVDRIYVAVRHPRLRGLRSPQAAAAVCVLW 141  
QY 153 GITIGLVHLLKKMPTONGANLCSFSISCHTFQWHEAMP-LLEPFLPLGIILFCSARI 211  
Db 142 VLVIGSLV--ARWLLGIQEGG--FCFR-STRHNP--NSMRFPFLGFLPLAVVVFCSLKV 194  
QY 212 IWSLROR---QMDRHAKIKAITFIMVVAIVFVICFLP---SVVVRIRIFWLHTSGTON 265  
Db 195 VTALAQQPPTDVQQAETRAKRVWANLVVFCFLPLHVGLTVRLAVGW-----NA 247  
QY 266 CEVRSVDLAFITLSTFTYNSMLDPVYVYFSSPSF 301  
Db 248 CALLETIPRALYITSKLSDANCCCLDAICYYYMAKEF 283

Search completed: October 20, 2005, 06:34:05  
Job time : 75 secs